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Current methods of treating critical size bone defects (CSDs) include autografts 
and allografts, however both present major limitations including donor-site morbidity, 
risk of disease transmission, and immune-rejection. Tissue engineering provides a 
promising alternative to circumvent these shortcomings through the use of stem cells, 
three dimensional (3D) scaffolds, and growth factors. Cells receive signals from their 
microenvironment that determine cell phenotype, and a combination of physical cues and 
chemical factors is thought to have the most profound influence on stem cell behavior. A 
major focus of tissue engineering strategies is scaffold design to recapitulate in vivo 
microenvironmental architecture to direct stem cell lineage commitment. In combination 
with relevant microenvironment design, the success of bone tissue engineering strategies 
critically depends on the rapid formation of a mature vascular network in the scaffolds 
after implantation. However, conventional approaches fail to consider the role of the host 
response in regulating tissue ingrowth and extent of vascularization. The work presented 
here focuses on i) designing an osteomimetic 3D substrate to guide human embryonic 
stem cell (hESC) differentiation towards bone lineage, and ii) investigating the ability of 
the polyphenol resveratrol to harness the potential of the inflammatory response to 
enhance angiogenesis and osseointegration in 3D scaffolds for bone repair. 
The osteomimetic scaffold with native bone extracellular matrix (ECM) 
components successfully directed the osteogenic differentiation of hESCs. A 
microsphere-sintering technique was used to fabricate poly(lactic-co-glycolic acid) 
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(PLGA) scaffolds with optimum mechanical properties, and human osteoblasts 
(hOBs) were seeded on these scaffolds to deposit bone ECM. This was followed by a 
decellularization step leaving the mineralized matrix intact. hESCs were seeded on the 
osteomimetic substrates in the presence of osteogenic growth medium, and osteogenicity 
was determined according to calcium content, osteocalcin expression, and bone marker 
gene regulation. The results from this study demonstrate the potential of PLGA scaffolds 
with native bone ECM components to direct osteogenic differentiation of hESCs and 
induce bone formation.  
Engineered resveratrol nanoparticle-incorporated PLGA scaffolds enabled the 
concurrent (i) mediation of inflammatory (M1) to wound healing (M2) macrophage 
differentiation, (ii) natural release of angiogenic factors by M2 macrophages and (iii) 
enhanced osteogenic differentiation of human mesenchymal stem cells (hMSCs). To this 
end, we mapped the time-dependent response of macrophage gene expression as well as 
hMSC osteogenic differentiation to varying doses of resveratrol. Our results delineate the 
potential to synergistically control angiogenic factor secretion and downstream 
osteogenic signaling pathways by “dialing” the appropriate degree of resveratrol release 
from nanoparticle-incorporated PLGA scaffolds.  
vii 
 
TABLE OF CONTENTS 
DEDICATION ....................................................................................................................... iii 
ACKNOWLEDGEMENTS ........................................................................................................ iv 
ABSTRACT ............................................................................................................................v 
LIST OF TABLES .................................................................................................................. xi 
LIST OF FIGURES ................................................................................................................ xii 
LIST OF SYMBOLS ............................................................................................................. xiii 
LIST OF ABBREVIATIONS ................................................................................................... xiv 
CHAPTER 1: BONE TISSUE ENGINEERING ..............................................................................1 
 1.1 TISSUE ENGINEERING ............................................................................................1 
 1.2 BONE PHYSIOLOGY AND MICROENVIRONMENT .....................................................2 
 1.3 CHALLENGES TO BONE TISSUE ENGINEERING APPROACHES .................................4 
CHAPTER 2: CELL SOURCES FOR TISSUE ENGINEERING .........................................................9 
 2.1 INTRODUCTION ......................................................................................................9 
 2.2 PROGENITOR CELLS ...............................................................................................9 
 2.3 ADULT STEM CELLS ............................................................................................10 
 2.4 EMBRYONIC STEM CELLS ....................................................................................10 
  2.5 INDUCED PLURIPOTENT STEM CELLS ..................................................................12 
CHAPTER 3: METHODS TO RECAPITULATE IN VIVO MICROENVIRONMENT ...........................14 
 3.1 CELL-ECM  INTERACTIONS DETERMINE CELL PHENOTYPE ................................14 
 3.2 MATERIAL PROPERTIES INFLUENCE CELL BEHAVIOR .........................................18 
viii 
 3.3 CELL SHAPE GOVERNS PHENOTYPE ....................................................................18 
 3.4 SUBSTRATE TOPOGRAPHY PROVIDES IMPORTANT CELL-ECM SIGNALS .............19 
 3.5 NANOSCALE TECHNOLOGIES ...............................................................................24 
 3.6 MICROSCALE TECHNIQUES ..................................................................................28 
 3.7 SCAFFOLD DESIGN ..............................................................................................31 
CHAPTER 4: DESIGN OF AN OSTEOMIMETIC SCAFFOLD FOR ENHANCED HESC 
DIFFERENTIATION ...............................................................................................................35 
 
 4.1 INTRODUCTION ....................................................................................................35 
 4.2 SYNTHESIS OF PLGA MICROSPHERE SINTERED SCAFFOLDS................................36 
 4.3 HUMAN OSTEOBLAST CELL CULTURE AND PLGA SCAFFOLD SEEDING ..............36 
 4.4 DECELLULARIZATION AND ANALYSIS .................................................................37 
 4.5 HESC SEEDING ....................................................................................................39 
 4.6 CELL ATTACHMENT, GROWTH, AND MORPHOLOGY ............................................40 
 4.7 ASSESSMENT OF OSTEOGENIC DIFFERENTIATION ................................................41 
 4.8 STATISTICAL ANALYSIS .......................................................................................43 
 4.9 RESULTS ..............................................................................................................43 
 4.10 DISCUSSION .......................................................................................................53 
 4.11 CONCLUSION .....................................................................................................56 
CHAPTER 5: RESVERATROL AS A STIMULATOR OF OSTEOGENESIS AND MODULATOR OF 
INFLAMMATION ..................................................................................................................58 
 
 5.1 INTRODUCTION ....................................................................................................58 




 5.3 DIFFERENTIATION OF MONOCYTES TO MACROPHAGES .......................................62 
 5.4 EFFECT OF RESVERATROL ON M1 MACROPHAGE PHENOTYPE ............................62 
 5.5 HMSC CULTURE AND OSTEOGENIC DIFFERENTIATION WITH RESVERATROL ......63 
 5.6 ANALYSIS OF HMSC PROLIFERATION AND OSTEOGENIC DIFFERENTIATION .......65 
 5.7 RESVERATROL MODULATES INFLAMMATION BY INDUCING MACROPHAGE 
PHENOTYPIC SWITCH ...............................................................................................67 
 
 5.8 RESVERATROL DRIVES THE OSTEOGENIC DIFFERENTIATION OF HMSCS ............68 
 5.9 STATISTICAL ANALYSIS ......................................................................................72 
 5.10 CONCLUSIONS ...................................................................................................72 
CHAPTER 6: ENGINEERED RESVERATROL NANOPARTICLE-INCORPORATED SCAFFOLDS TO 
DIRECT OSTEOGENIC DIFFERENTIATION OF HMSCS AND MODULATE INFLAMMATION OF 
M1 MACROPHAGES ............................................................................................................74 
 
 6.1 INTRODUCTION ....................................................................................................74 
 6.2 FABRICATION OF PLGA RESVERATROL NANOPARTICLES ...................................75 
 6.3 SYNTHESIS OF PLGA MICROSPHERE-SINTERED SCAFFOLDS AND INCORPORATION 
OF NANOPARTICLES ...................................................................................................76 
 
 6.4 HMSC AND M1 MACROPHAGE SEEDING ON RESVERATROL-INCORPORATED 
PLGA SCAFFOLDS .....................................................................................................79 
 
 6.5 STATISTICAL ANALYSIS .......................................................................................80 
 6.6 RESULTS ..............................................................................................................80 
 6.7 DISCUSSION .........................................................................................................86 
 6.8 CONCLUSIONS .....................................................................................................91 
CHAPTER 7: SUMMARY OF FINDINGS ..................................................................................93 
CHAPTER 8: FUTURE WORK ................................................................................................96 
x 
REFERENCES .......................................................................................................................97 
APPENDIX A – COPYRIGHT PERMISSION ...........................................................................114 
  
xi 
LIST OF TABLES 
Table 4.1 Primers sequences used in qRT-PCR to analyze osteogenic differentiation of 
hESCs on osteomimetic PLGA ..........................................................................................44 
 
Table 5.1 Primers used for qRT-PCR to determine macrophage phenotype and hMSC 
differentiation .....................................................................................................................64 
 
Table 6.1 Chemical characteristics of PLGA used to design nanoparticles for resveratrol 




LIST OF FIGURES 
Figure 1.1 Inflammation Cascade ........................................................................................7 
Figure 3.1 Nanoengineered Platforms for PSC Differentiation .........................................17 
Figure 3.2 Fabrication of PLGA Microsphere-sintered Scaffolds .....................................33 
Figure 4.1 Proliferation of hOBS on PLGA Scaffolds ......................................................46 
Figure 4.2 Analysis of Osteomimetic Scaffolds ................................................................47 
Figure 4.3 SEM Images of hESCs on Scaffolds ................................................................49 
Figure 4.4 Proliferation of hESCs on 3D Substrates .........................................................50 
Figure 4.5 Confocal Images of day 35 Differentiated hESCs ...........................................51 
Figure 4.6 Osteogenic Differentiation Analysis of hESCs ................................................52 
Figure 5.1 Gene Expression of M1 Macrophages Exposed to Resveratrol .......................70 
Figure 5.2 Osteogenic Differentiation Analysis of hMSCs Cultured with Resveratrol ....71 
Figure 6.1 Resveratrol Nanoparticle Characterization .......................................................82 
Figure 6.2 Gene Expression of M1 Macrophages Cultured on Resveratrol Nanoparticle -
incorporated PLGA Scaffolds ............................................................................................84 
 
Figure 6.3 hMSC Proliferation and Differentiation on Resveratrol Nanoparticle -
incorporated PLGA Scaffolds ............................................................................................85 
xiii 
 
LIST OF SYMBOLS 
α         ALPHA 
β         BETA 
°          DEGREES 
γ         GAMMA 
κ         KAPPA 














LIST OF ABBREVIATIONS 
 
2D .............................................................................................................. Two Dimensional 
3D ............................................................................................................ Three Dimensional 
AD-hMSCs .......................................... Adipose-derived Human Mesenchymal Stem Cells  
ANOVA ............................................................................................... Analysis of Variance 
ALP ..................................................................................................... Alkaline Phosphatase 
BM-hMSCs ................................. Bone Marrow-derived Human Mesenchymal Stem Cells 
BMP-2 .................................................................................. Bone Morphogenetic Protein-2  
CAD ............................................................................................... Computer Aided Design 
CNT........................................................................................................... Carbon Nanotube 
CSD ........................................................................................................ Critical-size Defect 
DAPI .................................................................................... 4’-6’diamidino-2-phenylindole 
DI .......................................................................................................................... Deionized 
DMEM ........................................................................ Dulbecco’s Modified Eagle Medium 
DMSO .................................................................................................... Dimethyl Sulfoxide 
EB ............................................................................................................. Embryoid Bodies 
EC ............................................................................................................... Endothelial Cell 
ECGF1 ...................................................... Platelet-derived Endothelial Cell Growth Factor 
ECM ...................................................................................................... Extracellular Matrix 
FAK.................................................................................................. Focal Adhesion Kinase 
FBS ........................................................................................................Fetal Bovine Serum 
xv 
FGF ............................................................................................... Fibroblast Growth Factor 
hESC ...................................................................................... Human Embryonic Stem Cell 
hMSC ................................................................................ Human Mesenchymal Stem Cell 
hOB .................................................................................................. Human Osteoblast Cell 
hiPSC ....................................................................... Human Induced Pluripotent Stem Cell 
hPSC ...................................................................................... Human Pluripotent Stem Cell 
IFNγ ......................................................................................................... Interferon Gamma 
IL-1β ........................................................................................................ Interleukin-1 Beta 
IL-4 ................................................................................................................... Interleukin-4 
IL-6 ................................................................................................................... Interleukin-6 
IL-10 ............................................................................................................... Interleukin-10 
IL-13 ............................................................................................................... Interleukin-13 
LPS ......................................................................................................... Lipopolysaccharide 
MCP-1 ...............................................................................Monocyte Chemotactic Protein 1 
MES .......................................................... 2-morpholinoethanesulfonic Acid Monohydrate 
MEF ........................................................................................ Mouse Embryonic Fibroblast 
MRC-1 ............................................................................ Macrophage Mannose Receptor 1 
MTS ........... [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium 
MW .......................................................................................................... Molecular Weight 
MWNT ..................................................................................... Multiwall Carbon Nanotube 
NF-κB .............................................................................................Nuclear Factor Kappa B 
NO ..................................................................................................................... Nitric Oxide 
OCN .................................................................................................................... Osteocalcin 
OSM ................................................................................................................. Oncostatin M 
xvi 
PAA........................................................................................................... Poly(acrylic acid) 
PBS ............................................................................................. Phosphate Buffered Saline 
PEG ..................................................................................................... Poly(ethylene glycol) 
PEGDA ............................................................................. Poly(ethylene glycol) Diacrylate  
PDGF ................................................................................... Platelet-derived Growth Factor 
PDMS ................................................................................................ Polydimethyl Siloxane 
PF4 .............................................................................................................. Platelet Factor 4 
PGA......................................................................................................... Poly(glycolic acid) 
PGE2 .......................................................................................................... Prostaglandin E2 
PGS ................................................................................................. Poly (glycerol sebacate) 
PLA ............................................................................................................. Poly(lactic acid) 
PLGA .......................................................................................Poly (lactic co glycolic) acid 
PLLA....................................................................................................... Poly(L-lactic acid) 
PLO ............................................................................................................. Poly-L-ornithine 
PMA ................................................................................... Phorbol 12-myristate 13-acetate 
PMGI................................................................................................. Polymethylglutarimide 
PPARγ2 .............................................. Peroxisome Proliferator-activated Receptor Gamma  
PV ......................................................................................................... Poly(vinyl) Alcohol 
qRT-PCR............................................. Quantitative Real Time Polymerase Chain Reaction 
RPM .....................................................................................................Rotations per Minute 
RUNX2 ......................................................................... Runt-related Transcription Factor 2 
SEM ..................................................................................... Scanning Electron Microscope 
SIRT-1...................................................................................................................... Sirtuin 1 
SWNT ................................................................................... Single Wall Carbon Nanotube 
xvii 
TCPS .......................................................................................... Tissue Culture Polystyrene 
TEM ...............................................................................Transmission Electron Microscope 
TGF- α.......................................................................... Transforming Growth Factor Alpha 
TGF-β .............................................................................. Transforming Growth Factor Beta 
TNF-α..................................................................................... Tumor Necrosis Factor Alpha 
UV ........................................................................................................................ Ultraviolet 



















CHAPTER 1: BONE TISSUE ENGINEERING 
 
1.1 Tissue Engineering  
In recent years, tissue engineering has emerged as a potential method for treating 
numerous diseases and regenerating damaged cells. By applying engineering approaches 
to knowledge of biological systems, a tissue engineered substitute can be generated to 
restore, replace, or maintain partial if not entire organ function [1]. The key to tissue 
engineering strategies is coordinating cell behavior with specific growth factors and 
biomaterials in order to regenerate functional tissues, however this is difficult to 
experimentally control in vitro.  
Like many tissues in the body, bone has a natural ability to repair minor injuries 
resulting from disease or small fractures. Despite this, it is estimated that over 800,000 
bone graft procedures are completed yearly in the United States to facilitate repair from 
large-scale trauma [2-4]. Current treatment methods for critical-sized defects (CSDs) 
include (i) autografts, where the patient’s own bone tissue is removed from one area and 
placed in the site of deficiency, (ii) allografts, where bone from a cadaver is used to 
replace the damaged tissue, (iii) and synthetic grafts, where manufactured materials are 
implanted and used to treat the CSD [5-7]. Autografts are considered the gold standard in 
clinical applications because of their osteoconductivity, osteoinductivity, and 
osteogenecity, however a secondary surgery is required for implementation. There is also
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a risk of disease transfer, rejection by the host, and large bone defects cannot be treated 
by autografts [8-13]. Long-term storage of bone tissue for allografts causes bone 
architecture to dramatically weaken and most of the osteoprogenitor cells are no longer 
viable. Synthetic grafts cannot fully incorporate with the host tissue and are susceptible to 
fatigue, fracture, and wear [14]. Therefore, there is a need for better treatment options for 
patients with CSDs, and tissue engineering offers bone graft alternatives.  
 
1.2 Bone Physiology and Microenvironment 
 
  Bone macrostructure generally has two layers, which includes the outer dense 
compact bone and the inner spongy trabecular bone.  The compact, or cortical bone, 
provides strength and support to the structure. The trabecular bone is porous with cells 
interwoven between calcified lattices.  Simply described, bone architecture can be broken 
down into this sequential arrangement: (i) the macrostructure which is made up of 
cortical and cancellous bone, (ii) the microstructure which is composed of osteons, 
haversian systems, and trabeculae, (iii) the submicrostructure which is comprised of the 
lamellae, (iv) the nanostructure which is predominately composed of collagen I fibers, 
and (v) the sub-nanostructure made up of mineralized matrix, smaller collagen subunits, 
and other organic proteins [15]. 
The extracellular matrix (ECM) is a dynamic arrangement of molecules such as 
collagen, con-collagenous glycoproteins, hyaluronan, and proteoglycan that are produced 
by cells, and in turn, regulate cell phenotype [16]. Native bone ECM is mainly composed 
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of type I collagen, upon which carbonated apatite is laid down to create a crystalline 
anisotropic fibril [17]. Serum albumin and α2-HS-glycoprotein are noncollagenous 
proteins that bind to hydroxyapatite due to their acidic properties [18]. Other 
noncollagenous proteins found in bone ECM include osteocalcin, alkaline phosphatase, 
osteonectin, osteopontin, and bone sialoprotein [18]. Cells residing in bone ECM secrete 
growth factors, matrix-degrading enzymes, and inflammatory mediators [16]. 
Bone is a highly vascularized tissue. The nutrient or diaphyseal artery, periosteal 
arteries, metaphyseal arteries, and epiphyseal arteries are the four arterial inputs that 
supply nutrients in adult bones.  The nutrient artery is responsible for the bulk of the total 
blood supply with over 50% of the blood flow due to its arterial output [19, 20].  
Periosteal arteries are responsible for the membrane covering the outside of bones called 
the periosteum.  The periosteum is a significant source of stem cells and has been utilized 
in previous regenerative studies [21, 22].  The diaphyseal nutrient artery enters the shaft 
through one or two nutrient foramina leading into the nutrient canals.  These arteries then 
enter the medullary cavity where they divide into ascending and descending branches to 
supply the cortical and marrow microcirculations.  The cortical branches of the arteries 
passing through the endosteal canals feed the capillaries in the Haversian and 
Volkmann’s canals and generally conform to the canal shape [23].  For bone marrow 
circulation, capillaries drain into vascular channels surrounded by a layer of fenestrated 
endothelium [24, 25].  The central venous sinus is responsible for the draining of the 
veins and runs along the paths of the nutrient arteries and leaves the bone through veins 
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[20, 23].  Blood flow in the bone generally occurs at 5-20 ml/min per 100 grams of wet 
bone tissue [23]. 
1.3 Challenges to Bone Tissue Engineering Approaches 
Although much progress has been made in the field of tissue engineering, critical 
barriers such as lack of scaffold vascularization, the host inflammatory response, and the 
need to use high doses of growth factors to differentiate cells must be overcome in order 
to effectively create functional tissues. In dealing with vascularization, tissue engineering 
meets a mass transfer challenge, which limits scaffold construct size in vivo regardless of 
tissue specific goals.  The majority of cells are situated within 100-200 microns [26] of 
capillaries where sufficient oxygen and nutrition is provided and metabolic waste is able 
to be transported [27].  It is difficult to engineer scaffolds less than a few hundred 
microns thick, therefore the ability for angiogenesis to occur in large scaffolds becomes a 
critical consideration. 
Another important factor is translating in vitro success to in vivo applications by 
accounting for the host immune response to implanted biomaterials that can lead to graft 
rejection. This reaction protects the body from harmful intruders and is beneficial on 
small time scales, but chronic inflammation can interfere with tissue engineering 
approaches to repair damaged tissue. The complicated interplay of cells and cytokines at 
the interface of an implanted biomaterial that governs success versus failure of an implant 
is still difficult to understand, but must be deconstructed in order to properly design an 
approach to harness inflammation and promote wound healing. 
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After a biomaterial is inserted into the host tissue, a sequence of reactions occur 
(Figure 1.1). First, injury to the vasculature causes blood to contact the material. Proteins 
from the serum bind to the implanted biomaterial and form a provisional matrix 
composed of fibrin, platelet granule components such as thrombospondin, transforming 
growth factor alpha (TGF-α) transforming growth factor beta (TGF-β), platelet-derived 
growth factor (PDGF), platelet factor 4 (PF4), and platelet-derived endothelial cell 
growth factor (ECGF1) [28]. Monocytes exit the capillaries, attach to the matrix that has 
formed on the biomaterial surface, and differentiate into pro-inflammatory M1 
macrophages. M1 macrophages release cytokines such as tumor necrosis factor alpha 
(TNF-α), interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and monocyte chemotactic 
protein 1 (MCP-1) that drive the acute inflammation response [29, 30]. The next event in 
the host response to an implanted biomaterial is chronic inflammation, which is defined 
by the presence of macrophages, monocytes, lymphocytes, blood vessel proliferation, and 
connective tissue formation [31-34]. Foreign body giant cells and macrophages will 
generally exist at the tissue-implant interface for the duration of the biomaterial’s lifetime 
[35-39]. A fibrous capsule usually forms around the foreign body reaction, separating the 
biomaterial from the host tissue [28]. In some tissue types, acute inflammation stimulates 
M1 pro-inflammatory macrophages to change phenotype into wound healing M2 
macrophages. This polarization from M1 to M2 is a critical component of avoiding graft 
and biomaterial rejection.  
Several approaches have been taken to control host inflammation in response to 
implanted biomaterials such as casing the scaffold with biocompatible coating, 
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incorporating anti-inflammatory pharmaceuticals in the substrate, and releasing 
angiogenic growth factors at the site of graft insertion. Biocompatible material coatings 
generally rely on creating a hydrophilic boundary between the implant and the host tissue 
[40, 41] which lessens the immune response, and subsequently maintains functionality of 
the implant for a slightly longer time period than an unmodified substrate [42-44]. 
Natural and synthetic polymers are typically used for this process, however, natural 
polymers can be immunogenic, decompose quickly at elevated temperatures that are 
necessary in manufacturing processes, and can exhibit much material inconsistency [41]. 
On the other hand, synthetic polymers offer the ability to tune the material specifically 
for the application, but generally have low adhesion capabilities for binding to the 
biomaterial, low mechanical strength, toxic chemicals are usually used to crosslink the 
polymer, and synthetic polymers present biocompatibility issues [41, 45].  Another well-
utilized method of promoting implanted material success is to induce angiogenesis using 
vascular endothelial growth factor (VEGF) [46-48]. Although somewhat successful, this 
method can overexpose tissues to growth factors which can cause arthritis or tumor 
formation [49-51]. Additionally, angiogenic growth factor release is not effective since 
multiple signals are required in the neovascularization cascade and temporal release of 
the cytokines is difficult to control. Anti-inflammatory drugs inhibit secretion of 
inflammatory mediators like leukotrienes and prostaglandins, reduce the amount of 
inflammatory cells, and lessen fibroblast recruitment at the site of implantation [52]. 
These drugs are typically administered systemically, therefore a drawback of this method 





Figure 1.1 Inflammation cascade after implantation of a biomaterial. 1) Biomaterial is implanted, and 2) 
proteins from the disrupted capillaries adsorb to the biomaterial surface. 3) Monocytes that are 
circulating in the vasculature migrate to the site of implantation, and 4) differentiate into M1 
macrophages. 5) M1 macrophages are pro-inflammatory and initiate the host inflammation response by 
6) releasing cytokines to 7) recruit fibroblasts for fibrous capsule formation. 
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inflammatory drugs such as corticosteroid drugs downregulate VEGF, thus inhibiting 
new blood vessel formation necessary for nutrient exchange in the implanted tissue [54, 
55].
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Choosing the correct cell type as part of a tissue engineering approach to create a 
functional bone graft substitute is essential for success of the implant. Cell types such as 
lineage committed progenitor cells, adult stem cells, and pluripotent stem cells all present 
viable options. Cell type selection is an important factor to consider, as cells seeded on 
scaffolds may stimulate signaling events that trigger host cells to migrate and integrate 
with the newly formed tissue, thus accelerating wound healing process following scaffold 
implantation. 
 
2.2 Progenitor Cells 
Progenitor cells are lineage-committed and maintain the tissue in which they 
reside [56]. These progenitor cells have been discovered in muscle tissue [57], cartilage 
[58], bone [58, 59], tissue in the central nervous system [60], in the bulge of the hair 
follicle [61], as well as many other locations. Like human mesenchymal stem cells 
(hMSCs), progenitor cells have a finite limit to proliferation and follow Hayflick’s limit 
of 50-70 population doublings [56, 62]. Progenitor cells have the advantage of patient 
specific treatment, however their narrow differentiation capabilities and limited 
proliferation potential present severe drawbacks.  
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2.3 Adult Stem Cells 
Numerous studies have demonstrated the potential of human mesenchymal stem 
cells in bone tissue engineering applications [63-68]. While they eliminate the 
controversy surrounding human embryonic stem cells (hESCs), they also present 
disadvantages such as the loss of proliferation capabilities with increasing passages and 
their infrequency in the stroma indicates a limited population of cells that can actually 
differentiate into osteogenic lineage [69, 70]. Studies conducted in animal models 
demonstrated that the amount of bone formed from hMSCs was insufficient to bridge a 
large bone defect [71]. Another shortcoming with using hMSCs for tissue engineering 
studies is that multipotency limits their differentiation potential to specific cell types [73, 
74].  However, when exposed to the correct chemical signals, adipose-derived hMSCs 
(AD-hMSCs) can differentiate towards osteogenic, chondrogenic, adipogenic, myogenic, 
and hepatic lineages, as well as become endothelial cells [75-78]. Bone marrow-derived 
hMSCs (BM-hMSCs) are a type of adult stem cell that can differentiate to bone, 
cartilage, muscle, ligament, tendon, adipose, and stroma lineages [79-82]. Although 
hMSCs have disadvantages, their ability of patient-specific treatment and differentiation 
capabilities into osteogenic lineage offer immense potential for use in bone tissue 
engineering strategies. 
2.4 Embryonic Stem Cells 
Both human mesenchymal stem cells and human embryonic stem cells have been 
investigated as a source of new bone tissue for grafts. hESCs possess the unique ability to 
self-renew and have the potential to differentiate into any cell type formed from the three 
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germ layers [83, 84]. hESCs offer a promising tool for biomedical research as they can be 
used in developmental studies, disease modeling, drug testing, and regenerative medicine 
[85]. These stem cells are derived from the inner cell mass of a pre-implantation embryo 
during the blastocyst stage [86-88]. The maintenance and culture of hESCs usually 
involves growing cells in feeder-dependent or feeder-free conditions, and cells are kept in 
colonies in order to preserve an undifferentiated state. Embryoid bodies (EBs) are 
commonly used to mimic the three-dimensionality of development during gastrulation 
and the formation of the three germ layers in vivo [89]. The limitation of employing EBs 
for differentiation studies arises from the fact that the yield of desired cells is much lower 
than the initial amount of cells [90]. In order to use hESCs for differentiation 
experiments, cells must retain pluripotency and self-renewal capabilities, and it is 
imperative to parse the underlying developmental mechanisms involved in osteogenesis 
in order to successfully engineer bone tissue.  
hESCs are promising candidates for bone tissue engineering applications since 
they can differentiate into every cell type found in bone [91-96].  Osteoblasts, osteoclasts, 
nerve cells, and vascular cells all contribute to bone architecture and function, and given 
the correct signals, hESCs will become these cell types [97]. hESCs are a superior choice 
for bone tissue regeneration strategies based on their pluripotency and proliferation 
capabilities, but they offer obstacles to overcome as well.  
hESCs are difficult to culture and scaffold surface modification is required for cell 
attachment; substrates traditionally have been coated with protein cocktails such as 
Matrigel or Geltrex to promote cell adhesion. Bone-forming osteoblast cells or 
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osteoprogenitor cells can also be used to deposit natural extracellular matrix proteins onto 
the substrate for hESC attachment. To date, great strides have been taken in using native 
bone components to create scaffolds to promote the growth of osteoblast-like cells, 
however most approaches focus on one element of the ECM as opposed to the entire 
network [98-107]. Decellularized scaffolds composed of the organic and inorganic 
elements of bone ECM are osteoinductive as well as osteoconductive. The interactions 
between cells and the ECM have the ability to define cell development and function 
[108]. By using osteoblasts to deposit ECM, a natural bone microenvironment is created 
that will stimulate hESCs to differentiate into osteogenic lineage. Although numerous 
studies have shown the potential of decellularized scaffolds, there is a lack of 
characterization of the signals involved in using natural ECM to direct the differentiation 
of hESCs and there is a need for determining which spatial and temporal cues control the 
diverse development of bone. 
 
2.5 Induced Pluripotent Stem Cells 
 
Induced pluripotent stem cells (iPSCs) were first created by introducing four 
pluripotency transcription factors (Oct3/4, Sox2. C-Myc, and Klf4) to a mouse fibroblast 
cell, after which the fibroblast exhibited properties of undifferentiated hESCs [109]. 
These stem cells have the ability to differentiate into cells of all three germ layers, can 
self-renew, and proliferate indefinitely [110, 111]. Unlike hESCs, iPSCs offer the 
opportunity for patient specific treatment since somatic cells can be taken from the target 
host, reprogrammed through the addition of transcription factors, cultured to increase cell 
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number, differentiated towards the desired lineage, and finally implanted back into the 
patient. Since the genetic material in the implanted cells is the same as in the host’s cells, 
the risk of immunorejection is low. 
One obstacle with using iPSCs for tissue engineering approaches is that this cell 
source uses a viral vector to introduce the pluripotency transcription factors to the stromal 
cell. This has raised concern regarding unwanted side effects in patients, even though the 
vector portion is composed of just the viral envelope. Another barrier for using hESCs 
and iPSCs in regenerative medicine is that teratoma formation in implanted tissue can 
occur when cells have not fully and uniformly differentiated into the target tissue [112, 
113]. Therefore, it is extremely important to develop a direct approach to exclusively 
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CHAPTER 3: METHODS TO RECAPITULATE IN VIVO MICROENVIRONMENT 
 
3.1 Cell-ECM Interactions Determine Cell Phenotype 
 
Although hESCs, iPSCs, and hMSCs are promising cell sources for tissue 
engineering applications and invaluable tools for studying developmental biology, there 
are still many fundamental aspects of stem cell biology that are unknown. Specifically, 
researchers are striving to understand and deconstruct the mechanisms by which the 
microenvironment effects lineage determination, as well as cell phenotype and function.  
The native microenvironment is composed of the ECM, which is a network of 
proteins that provides physical and chemical cues determining cell behavior [114-117]. 
Cell biologists have analyzed numerous cytokines and soluble factors responsible for 
stem cell regulation, however, recent studies indicate that these soluble factors work in 
conjunction with the insoluble components present in the ECM such as adhesive, 
mechanical, and topographical cues [118-122]. Specifically, insoluble factors are made 
up of collagens, non-collagenous glycoproteins (laminin, elastin, fibronectin), and 
hydrophilic proteoglycans [123]. Stem cells can detect and respond to signals 
simultaneously presented in the microenvironment; cell mechanotransduction machinery 
converts these soluble and insoluble cues to signal upregulation of various genes and 
subsequent lineage commitment [122].  
Past biomaterial design has focused on microscale technologies to drive stem cell 
lineage commitment, but the in vivo tissue structure also provides cues to cells at a 
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nanoscale level. Furthermore, cells tend to respond to some microscale fiber scaffolds the 
same way that they do when cultured on a 2D polystyrene cell culture plate. Cell 
morphology becomes flat, which causes a lopsided attachment of focal adhesions [123]. 
Therefore, for certain tissue engineering approaches to generate softer tissues, providing 
signals at the microscale level might be physiological inconsistent for directing stem cell 
differentiation [124]. There is a need to engineer functional nanoscale microenvironments 
for tissue engineering applications. The field of nanotechnology in relation to tissue 
engineering involves designing novel materials with at least one dimension between 1-
100 nm to use as scaffolds for influencing cell behavior [125]. Section 3.5 will discuss 
different techniques for creating biomaterials with nanoarchitectural features. 
Nano and microscale signals such as shear stress, strain, material elasticity, 
topographical variation, and cell shape all affect cellular function and lineage 
specification. Cells experience mechanical cues such as stress and strain in the in vivo 
microenvironment. Muscle contraction and relaxation, bone compression and 
decompression, cell migration, fluid flow, and tissue regeneration all cause variations of 
mechanical forces in the body. The ECM also has a range of elastic moduli that generate 
physical stimuli for attached cells through focal adhesions. These mechanical cues are 
transduced through focal adhesion kinase (FAK) and Src family signaling [122]. 
Furthermore, integrins are activated by stress, strain, and differing elastic moduli. This in 
turn increases focal adhesion strength and upregulates integrin mediated signaling 
throughout the cell. The biochemical pathways that are activated as a result of physical 
stimuli are part of a positive-feedback loop which further activates actomyosin 
cytoskeleton tension and increases focal adhesion strength [122, 126, 127]. As a result, 
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researchers have explored how varying signals alter hESC behavior in vitro with hopes of 
determining what physical forces, separately or in combination, control lineage 
commitment.  
The effect of mechanical cues on cell function has been reviewed for many cell 
types, and has established general knowledge regarding cell behavioral responses [121, 
128-131]. Recent studies have made great strides in determining the impact physical 
stimuli have on hESCs. For example, the effect of cyclic strains on hESCs inhibited 
differentiation and increased self-renewal [132]. This was caused by the upregulation of 
TGFβ1, Activin A, and nodal which initiates the phosphorylation of Smad 2/3 [133]. 
Another study showed that cyclic stress through integrin-mediated adhesions induces 
spreading of mouse ESCs and decreased the expression of pluripotency marker Oct3/4 
[134]. 
Shear flow has also been investigated as a mechanical cue for ESCs since it is a 
dynamic stress found in vivo, most commonly exerted on cells in the circulatory system 
[135]. Mouse ESCs placed in a microfluidic chamber demonstrated that a higher flow 
rate of 1.1 μL/min produced larger, round colonies as compared to slower rates of 0.001 
μL/min and 0.019 μL/min [136]. This rounded phenotype indicates decreased 
cytoskeletal tension. When ESCs are subjected to highly controlled shear flow they 
differentiate into endothelial or specialized cardiovascular cells [137, 138]. Furthermore, 
ESCs exposed to culture conditions with shear stress express greater levels of endothelial 
















Figure 3.1 Biomaterials with (a) fibrous architecture, (b) surface roughness and 
varying nanotopographical features, and (c) nano grooves/ridges provide cues to 
cells. These microenvironmental signals, along with other mechanical cues 
mentioned in this review, have the ability to cause cell migration, adhesion, 
differentiation, proliferation, and alignment. 
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3.2 Material Properties Influence Cell Behavior 
A recent study demonstrated that matrix elasticities of 1 kPA, 8 kPa, and 25 kPa 
lead hMSCs respectively towards neurogenic, myogenic, and osteogenic lineage [131]. 
This discovery, along with the known fact that matrix mechanics are a definitive factor in 
tissue morphogenesis and cell function [140-142], influenced researchers to investigate 
the response of ESCs to material properties.  
ESCs are generally cultured on stiff 2D cell culture plates. Studies have shown 
that cell traction and colony stiffness increase when ESCs are grown on traditional rigid 
substrates, which also correlates with the downregulation of Oct3/4 in mouse ESCs [134, 
143]. Cells grown on soft polyacrylamide gels with a stiffness of 0.6 kPA formed round, 
compact colonies that had high Oct3/4, Nanog, and Alkaline Phosphatase expression 
compared to the polystyrene plates with stiffness of approximately 4 MPa [143]. This 
study demonstrated that soft materials cause cells to exhibit low traction forces and 
colony stiffness, and as a result, self-renewal and pluripotency of ESCs is maintained.  
 
3.3 Cell Shape Governs Phenotype 
Stem cell shape regulates physiology, controls proliferation, and ultimately 
governs lineage specification [144, 145]. Cells have particular shapes that optimize 
carrying out specific cellular functions: neurons have long bodies to efficiently deliver 
signals that can span the entire length of the human figure, where adipocytes are spherical 
to store lipids [122]. From a developmental point of view, signals from the stem cell 
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niche induce conformational changes which then influence tissue structure and purpose 
[146-148].  
One of the first experiments demonstrating the impact of cell size on behavior 
used 20 μm2 and 75 μm2 fibronectin islands to show that size directly controls apoptosis 
and proliferation, respectively [149]. Furthermore, studies have shown that restricting 
hESC colony size regulates differentiation, with smaller cell groupings favoring 
endoderm commitment over ectoderm [150]. Patterning adhesive ligands to control hESC 
colony size determined large colonies with a high cell density microenvironment promote 
pluripotency, controlled through a BMP-mediated Smad1 gradient. This gradient forms 
due to the interaction of hESCs and hESC-derived extraembryonic endoderm [151]. 
These findings are thought to occur due to cell-cell contact, varying mechanical stresses 
throughout the body of cells, and soluble factor gradients.  
 
3.4 Substrate Topography Provides Important Cell-ECM Signals 
Topography plays a key role in cell maintenance and function. Nanoscale 
architecture has grooves, ridges, pits, and pores in vivo; for example proteins in the ECM 
are generally arranged in a fibrous manner with these topographical properties. These 
fibrillar networks are approximately 10-100 nanometers but can be several microns [152, 
153], and the bone marrow contains numerous nanoscale pores that provide additional 
cues for stem cells [135]. Nanotopography is important because cells receive signals 
through specific binding sites that integrins recognize, and integrin signaling is controlled 
through nanoscale ECM-cell interactions [124]. Surface features as small as 10 nm have 
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the ability to influence cell adhesion [154]. When cells bind to integrins, tyrosine kinase 
and phosphatase signaling is activated, and both are important for cell fate and gene 
expression [122]. Through these biophysical cues, stem cell adhesion and cytoskeleton 
organization are regulated, thus cell decisions regarding proliferation, migration, 
elongation, cell alignment, polarization and differentiation are impacted [152, 155-162]. 
Studies using MSCs determined that the nanoscale topography potentially acts through 
spatial control of ligands and regulatory factors, and the interplay between physical and 
biochemical cues determine cell morphology and phenotype [135]. This, among other 
principles discovered by examining hMSC response to alterations in topography, can be 
applied to human pluripotent stem cells (hPSCs).  
Topography is a powerful tool since, not only is cytoskeleton tension altered like 
in cell shape experiments, but entire molecular arrangement and dynamic organization of 
cellular adhesion mechanisms are effected [122]. Polymethylglutarimide (PMGI) 
nanofibers were used as scaffolds to maintain mouse ESC stemness and it was concluded 
that fiber density and structure were important factors in retaining pluripotency. This 
study also found that mouse ESCs had the ability to differentiate into all three germ 
layers on this substrate [163]. Studies observing the response of hESCs to 
nanotopography have used fibronectin coated poly(di-methyl siloxane) (PDMS) 
substrates with 600 nm ridges, 600 nm spacing, and 600 +/- 150 nm height. Single cells 
were placed on the surface for 24 and 48 hours, and it was determined that the 
nanotopographic surfaces increased cell alignment and elongation, but decreased 
projected cell area and proliferation [164]. An experiment utilizing polyamide 
nanofibrillar surfaces covalently linked to FGF-2 found that this substrate enhanced 
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hESC proliferation [165]. The use of fibrillar nano architecture in scaffolds has the 
potential to spatially align and organize cells while retaining pluripotency, however cell 
proliferation capabilities depends on the ridge size and surface chemistry of the scaffold 
and must be further optimized to sustain hPSC growth.  
Another study used UV-assisted capillary force lithography to create 350 nm 
ridge/groove pattern arrays, then demonstrated the ability of the surface topography to 
direct hESCs towards neuronal lineage in the absence of differentiation-inducing soluble 
factors [166]. Furthermore, neural differentiation of ESCs was demonstrated in an 
experiment using poly(L-lactic acid) (PLLA) electrospun nanofibers incorporated with 
single wall carbon nanotubes (SWNTs) and multi wall carbon nanotubes (MWNTs). 
Scaffolds containing the carbon nanotubes promoted greater differentiation towards 
neural lineage, shown by an upregulation of Map-2. Differentiated cells aligned on the 
fibers demonstrating the influence of physical cues on cell morphology and lineage 
commitment [167]. Another recent study also investigated the effects of topography on 
human iPSC differentiation towards neuronal lineage [168]. A PDMS substrate was 
patterned with ridges/grooves of width 350 nm and groove depth of 300 nm, then single 
cells were placed on the nanostructures and allowed to differentiate for 4 days. Cell 
alignment on the 350 nm width groove substrate was compared to surfaces with 2 μm and 
5 μm widths, and it was found that cells responded with the highest degree of alignment 
to the nanogrooves. Additionally, human iPSCs placed on the 350 nm substrate expressed 
the highest levels of neuroectodermal markers NPY and SYT4, demonstrating the 
importance of topography in guiding pluripotent stem cell phenotype. Collectively, these 
results indicate that controlling hPSC alignment on nanogroove structures directs cell 
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differentiation towards neuronal lineage, and ESCs on random electrospun fibers 
incorporated with carbon nanotubes will purposefully elongate with the direction of the 
fibers and upregulate neuronal marker gene Map-2. 
MWNT films were employed to investigate the response of hESCs to surface 
roughness. hESC colonies favored rougher surfaces for attachment, exhibited flattened 
morphology with standard colony size, and retained pluripotency when cultured on 
MWNT films [169].  A similar study grafted CNTs with poly(acrylic acid) (PAA) to 
form a thin film, and the results indicated that this substrate, in combination with neural 
growth factors, stimulates hESC differentiation towards neural lineage at a higher rate 
than a conventional poly-L-ornithine (PLO) substrate often used in generating neurons 
from stem cells [170]. Another study utilized an array of CNTs conjugated with ECM 
proteins to determine the hPSC behavioral response when cultured on this platform. This 
array was found to support undifferentiated hESC and iPSC growth as well as self-
renewal and pluripotency marker expression [171]. Furthermore, it was shown that both 
types of hPSCs cultured on the CNT arrays were able to differentiate towards ectoderm, 
mesoderm, and endoderm lineages [171]. The hPSCs grown on the CNT arrays were then 
directed towards spontaneous differentiation, and in reaction to the CNT topography, 
preferentially expressed mesodermal markers due to the physical stimuli exerted on the 
cells [171]. A similar study investigated culturing hESCs on a collagen/CNT matrix. 
Colonies were placed on tissue culture plates coated with gelatin, collagen, and 
collagen/CNTs and allowed to spontaneously differentiate. Colony morphology on the 
gelatin substrates was random and spread out, while hESCs on the collagen as well as the 
collagen/CNT matrices exhibited an elongated shape that aligned with the fibrils. By day 
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3, hESCs on the collagen/CNT surface expressed the early neural progenitor marker 
nestin significantly higher than the cells on the collagen substrate. By day 6, all three 
groups expressed nestin, with the highest levels detected in the collagen/CNT group 
followed by the collagen and gelatin groups, respectively [172]. These groundbreaking 
studies involving CNTs have provided insight on stimuli controlling hPSC lineage 
specification. CNT films maintain hPSC pluripotency and undifferentiated colony 
phenotype, substrates containing fibrillar architecture with CNTs promote hESC 
differentiation towards neural lineage, and CNT arrays exert physical forces on hPSCs 
that guide them towards mesoderm lineage commitment. 
In another study, surface nanoroughness of silica-based glass wafers was altered 
and hESCs were placed on the various substrates in single cells. hESCs on the control 
glass surface demonstrated highly branched morphology with many cytoplasmic 
extensions, while cells on the nanorough glass were compact with few, short filapodia. 
Cells on a rough surface patterned with square-shaped smooth islands favored attachment 
to the smooth glass instead of the nanorough areas and expressed pluripotent marker 
Oct3/4, and hESCs placed on an exclusively rough surface spontaneously differentiated. 
Proliferation of hESC colonies was determined by placing cells on smooth glass and 
nanorough substrates, and it was determined that doubling time of hESCs on the control 
surface was 41 hours compared to a slower 71 hour doubling time of colonies on the 
rough surface [173]. In opposition, a study showed that silica colloidal crystal with 
diameters of 120, 400, and 600 nm coated with collagen I maintained the expression of 
murine ESC markers in comparison to smooth glass. However, colonies exhibited 
reduced spreading on the surface with altered topography [174]. Another study coated 
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cell culture plates with poly[2-(methacryloyloxy)ethyl dimethyl-(3-
sulfopropyl)ammonium hydroxide], then demonstrated that hESC colonies cultured on 
this substrate maintained their proliferation, self-renewal, and pluripotency capabilities 
[175]. A unique study used graphene and graphene oxide to coat glass coverslips and 
observed mouse iPSC behavior on the different substrates. It was found that iPSCs on the 
graphene and smooth glass surfaces proliferated at similar rates, but cells on the graphene 
oxide substrate had greater adhesion and proliferation. The graphene substrate maintained 
cells at an undifferentiated state, while the graphene oxide surface promoted spontaneous 
differentiation [176]. Overall, rough surfaces promote PSC adhesion with a more 
compact morphology, however, studies have found opposing evidence for whether or not 
nanorough surfaces maintain pluripotency and an undifferentiated state, or promote 
spontaneous differentiation. There are also conflicting results determining if these 
surfaces foster or hinder proliferation, therefore more studies are warranted to understand 
how PSCs respond to rough culture substrates. 
3.5 Nanoscale Technologies 
The in vivo microenvironment is composed of channels, pores, and ridges that 
provide physical cues to cells at a nanoscale level [124]. Knowledge of how these factors 
influence stem cell behavior is necessary to effectively design scaffolds that differentiate 
stem cells to the desired lineage. To analyze the impact of nanofeatures on cell behavior, 
engineers and scientists have combined principles of chemistry, physics, material science, 
and biology to create specialized substrates. Fabrication techniques such as soft 
lithography, deposition of nanostructures, microfluidics, and electrospinning all create 
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ways for researchers to manipulate topography [177-179]. These platforms have been 
used to determine specific cues that regulate stem cell function.  
Electrospinning is a technique that can form a network of polymer fibers down to 
the size of 10 nm [180]. To generate electrospun scaffolds, a voltage is applied to a 
polymer solution, the charged solution is ejected though a needle, and electric forces 
stretch the polymer jet so that fibers with submicroscale diameters form on the grounded 
collector surface [181]. Since the fiber diameters are much smaller than cellular surface 
area, this platform allows cells to organize around the fibers [182] and attach with a 
spread morphology with numerous focal adhesions [183]. Another advantage of this 
technique is the ability to create electrospun scaffolds from synthetic as well as natural 
polymers [181]. However, one challenge with this fabrication method is that cells cannot 
migrate throughout the scaffold due to pore sizes being smaller than that of a cell [123]. 
Recent progress has overcome this limitation by using self-assembly of nanofibers 
around the cells [184]. Knowledge of protein self-assembly and optimization of 
noncovalent intermolecular interactions produced this revolutionary approach to forming 
the nanofibrillar architecture around cells without damaging them [185, 186]. This 
technique allows the scientist to spatially and mechanically organize cells, which is 
critical to tissue engineering strategies since cells in the body are arranged in specific 
patterns that form tissues and organs [123]. This fabrication process is able to create 
substrates that mimic grooves, ridges, and the fibrillar ECM structure, and recent 
advancements with assembling the scaffold material around target cells has overcome the 
previous inability of cells to infiltrate the scaffold.    
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The general method of soft lithography uses elastomeric stamps to print nanoscale 
polymers on a surface [187-190]. Patterned polymers can range from 30 nm to several 
microns [191]. This is a useful technique because the engineer has full control over 
spatial distribution of polymer molecules placed on the substrate, which subsequently 
determines cell spreading and shape [192-194]. Soft lithography is an invaluable tool 
because it creates a platform on which researchers can isolate and control mechanical 
cues exposed to single cells [195] and also pairs or triplets of cells [196]. This technique 
is very useful in deciphering cellular reactions to individual physical cues since the 
polymers can be easily manipulated to express specific mechanical characteristics. 
However, a limitation with this platform is that soft lithography is only able to provide a 
narrow range of ECM signals for the cell to receive, which is inconsistent with the many 
microenvironmental cues provided to cells in vivo.  
 
Hydrogels are a popular tissue engineering scaffold with proven success in 
medicine and biological research due to their tunable tissue-like properties [197-201]. 
The goal of hydrogel design is to mimic natural ECM, which is accomplished by 
crosslinking polymers. The intricate linking of these hydrophilic molecules forms a 
network with tissue-like viscoelastic mechanical properties, as well as similar interstitial 
flow to the in vivo microenvironment. Similar diffusive transport also occurs in hydrogel 
cell culture platforms, and hydrogels can be designed to incorporate cell adhesion ligands 
and other biologically relevant components [123]. Although hydrogels are an extremely 
moldable substrate and offer numerous advantages as scaffolds for tissue engineering, 
they have low mechanical strength, they are difficult to sterilize, and loading drugs and 
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cells in the matrix before crosslinking the material is difficult [202, 203]. Further 
optimization studies are warranted to overcome these barriers. 
Carbon nanotubes possess ideal qualities for tissue regeneration strategies such as 
tunable chemical and mechanical properties, electrical conductivity, cytocompatibility, 
and nanoscale dimensions that serve as topographical cues [204]. Furthermore, CNTs 
have numerous applications for directing cell behavior such as drug delivery, gene 
modifications, and incorporation in the in vitro 3D cell microenvironment to add 
roughness [205-207]. When placed in fetal bovine serum (FBS), proteins readily adsorb 
to the surface of CNTs subsequently promoting cell attachment [208]. Several studies 
have demonstrated the potential of CNTs for bone tissue engineering applications [209-
212], myoblastic cell attachment and growth [208] as well as neuronal cell proliferation 
[213], but little is known regarding the effect of CNTs on stem cell fate. In order to 
hypothesize how CNTs could influence pluripotent stem cell behavior, an analysis of 
studies conducted on the effect of CNTs on other cell types must be done, with further 
scrutiny on how individual characteristics of CNTs control the cellular response. Towards 
this goal, a recent study has shown that the mechanical properties of CNTs promote 
differentiation of MC3T3-E1 osteoblasts towards osteogenic lineage [209]. A study 
isolating the conductivity attribute of CNTs demonstrated that multiwall carbon 
nanotube-incorporated hydrogels increased cell proliferation of myocytes as well as 
fostered the growth of multinucleated cells with higher actin filament interactions as 
compared to the control groups [214]. CNTs can be functionalized to exhibit varying 
chemical properties that influence cell phenotype, shown in a study investigating single 
wall carbon nanotube conjugation with poly(m-aminobenzene sulfonic acid) and 
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poly(ethylene glycol) in which neurons exposed to more positively charged groups 
exhibited greater neurite length and had additional growth cones [215]. Since CNTs 
exhibit numerous traits that have the potential to impact cell lineage commitment, there is 
a need to delineate the effects of each specific CNT characteristic on hPSC behavior. 
 
Microfluidics allows for precise regulation of fluid flow and microenvironmental 
geometry, usually in the form of channels with similar dimensions to that of the cell type 
under investigation. Volumes can easily be controlled to levels of 10-18 liters [216], and 
the flow rates are manipulated so that shear stress in the in vitro microenvironment is 
optimized. Microfluidic platforms have been used extensively to study cell biology, 
specifically cellular adhesion forces [217], the cytoskeleton [218], and the culture of 
embryos [219-221]. This platform is useful in determining the influence of shear stress on 
individual cells, as well as mimicking the effects of capillary and interstitial flow, but the 
scale of this technique is not practical for larger magnitude tissue regeneration studies. 
 
3.6 Microscale Technologies 
Cellular scaffolds mimicking tissue generally have large, macroscale features that 
promote cell adhesion, migration, and proliferation.  However, microscale features are 
needed to allow vascularization of thick tissue requiring higher levels of oxygen diffusion 
than connective tissues, such as the skin [222, 223], bladder [224], and the cornea [225, 
226].  By altering the physical topography of 3D scaffold structures, cell function can be 
controlled through a variety of means such as cell-cell contact, cell morphology, and cell 
orientation [227, 228].   Micro-fabrication of vascular networks for scaffolds is generally 
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achieved using methods such as photolithography, 3D printing, and soft lithography 
[229-238].  The approach behind these methods is to allow oxygen into deeper portions 
of the developing tissue to stimulate in vitro vascularization and more efficient nutrient 
exchange. 
Photolithography is a highly utilized approach to creating substrates for tissue 
engineering strategies. This method creates micro-patterned scaffolds through the use of a 
photomask, which is an opaque plate that allows light to pass through only at specific 
transparent points that are composed of patterns [239-243].  This approach uses pre-
polymers that crosslink when exposed to UV light, a photomask, and a photoinitiator. 
When the pre-polymer is placed under the photomask, only pre-polymer that is below the 
transparent regions is crosslinked, polymerized, and therefore patterned through light 
exposure. The photoinitiator catalyzes the reaction of the pre-polymer with the UV light, 
and is ideally nontoxic to cells. Micro-patterning hydrogels such as poly(ethylene glycol) 
[244-247], methacrylated hyaluronic acid [248-251], and gelatin methacrylate [252, 253] 
has been successful in tissue engineering approaches.  In a recent study [244], bio-active 
poly(ethylene glycol) diacrylate (PEGDA) was micro-patterend with adhesive ligand 
RGD in various concentrations and geometries. Endothelial cells were cultured on the 
substrates and cells formed cords resembling capillaries on 50 µm wide strips of RGD. 
Furthermore, cells formed cords at an RGD concentration of 20 µg/cm2, but did not 
arrange in this manner at higher RGD concentrations.  Photolithography is a powerful yet 
simple tool for studying tissue morphogenesis. The fabrication process is straightforward 
and provides a method to study cellular phenotype in response to microscale structures.   
 
 30   
3D printing, or rapid prototyping, is a relatively new method of creating three 
dimensional objects.  Rapid prototyping is an approach to fabricate 3D structures from 
model data usually using a layer-by-layer approach.  These processes generally follow a 
similar pattern including the initial computer aided design (CAD) model of the part, 
conversion to an appropriate file format, slicing the file into thin layers for deposition, 
and the final layer by layer construction phase.  CAD programs such as SolidWorks or 
AutoCad are used in the first step to create the customized part for manufacture, and then 
CAD files are converted to the standardized STL file format.  The initial study that 
started the rapid prototyping methods was Charles W. Hull in 1986 who patented 
stereolithography (US Pat. 4,575,330).  This method utilizes a layer-by-layer technique to 
building 3D models with photolabile polymers, or resin, that are cured when exposed to 
UV light.  This happens with a platform that is submerged in a container of uncured resin 
slightly below the platform.  A focused UV laser then traces out the first cross section 
leaving the remaining tray of resin in liquid form.  The platform slowly moves down 
leaving the laser to trace each cross section of the part until a fully cured part remains.  
This approach has been used for hard tissue applications [232] as well as soft tissue 
applications [254-256].  For a soft tissue study [254] a group used poly(ethylene glycol) 
hydrogels at differing PEGDA concentrations and laser energies for use in determining 
hydrogel thickness.  These hydrogels were used to study encapsulated cell viability in 
fabricated 3D PEGDA structures, which showed at least 87% viability after 24 hours, 
thus proving that rapid prototyping is a viable option for soft tissue engineering. 
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As mentioned in section 3.5, soft lithography is a valuable tool in the in the field 
of tissue engineering with capabilities for duplicating nanometer to micrometer 
structures. This is accomplished using stamps, molds, and photomasks. Furthermore, soft 
lithography can be combined with microfluidic methods for vascular tissue engineering 
strategies. This approach uses soft lithography to create branched networks mimicking in 
vivo vasculature, seeds cells on the substrates, and connects the system to a microfluidic 
perfusion bioreactor to replicate shear stress [257]. Furthermore, 3D vascularized 
scaffolds have been created by using a layer by layer microfluidic approach [237, 258, 
259].  Microfluidic channels have been generated using polymers such as PDMS, PLGA, 
and PGS, and endothelial cells are cultured on these substrates for vascular engineering 
approaches [229, 260, 261].  This is a precise technique to stimulate the formation of 
capillaries in a way that replicates in vivo structures. A recent study used soft lithography 
techniques to pattern non-adherent agarose templates in order to recapitulate early actions 
of angiogenesis [262]. Human mesenchymal stem cells and human umbilical vein 
endothelial cells were placed on these substrates, and VEGF expression was monitored as 
a means of determining mechanical impacts of the microenvironment on angiogenesis. 
 
3.7 Scaffold Design for Bone Tissue Engineering 
Tissue engineering presents a new avenue for developing bone grafts by 
combining the use of cells, specific signaling molecules, and three-dimensional (3D) 
substrates [263-266]. Recent efforts towards developing bone graft substitutes focus on 
3D scaffold design. The 3D matrix should mimic the structure of bone, in which porosity 
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and mechanical strength are important characteristics. A scaffold should also guide the 
integration of host cells, the differentiation of transplanted cells, and promote bone ECM 
formation on the surface of the substrate [267]. In this spirit, biodegradable scaffolds 
provide a temporary matrix for cells to attach, proliferate, and deposit ECM [268-272]. 
Polymers such as poly(lactic acid) (PLA), poly(glycolic acid) (PGA) and their 
copolymers poly(lactic-co-glycolic acid) (PLGA) have demonstrated success in bone 
tissue engineering applications due to their biocompatibility, osteoconductivity, and 
mechanical properties [273-277]. Various scaffold fabrication methods used in tissue 
engineering studies include phase separation [278], freeze drying [279], solute leaching 
[280] and gas foaming [281].  Newer methods such as electrospinning [282] provide a 
porous structure, and this technique as well as 2D patterning are becoming increasingly 
popular in scaffold design. The phase separation technique utilized in this presented work 
is depicted in Figure 3.2.  
Towards this effort of directing cell behavior, various biomaterials as well as 
different cell types and signaling molecules have been investigated. Recent studies have 
examined the ability of mechanical signals to influence stem cell lineage commitment 
since cells in the body reside in different tissue niches with variable mechanical 
properties that effect cellular function. From this information, biomaterials have been 
designed to harness tissue-specific mechanical properties to guide stem cells to the 
targeted cell type. Specifically, 3D platforms with nano and microscale features are 
utilized since they offer a unique ability to mimic the physical cues that cells receive 
from their microenvironment. Researchers have developed materials with tunable matrix 
 
 33   
 
Figure 3.2 Fabrication of PLGA microsphere-sintered scaffolds. A mixture of 1:4 
PLGA dissolved in dichloromethane is slowly poured into a 1% Poly(vinyl alcohol) 
solution stirred at 330 RPM (1). Microspheres are stirred for 24 hours, then collected 
via vacuum filtration (2). After a lyophilization step, microspheres are sorted 
according to size by using a micron sieve (3). Microspheres are placed in stainless 
steel molds to form scaffolds (4), and heated for 4 hours at 85 °C to sinter (5). Final 








 34   






















CHAPTER 4: DESIGN OF AN OSTEOMIMETIC SCAFFOLD FOR 
ENHANCED HESC DIFFERENTIATION 
 
4.1 Introduction 
Scaffold design is a crucial component in bone tissue engineering strategies. The 
ideal scaffold should provide a substrate for cells to attach and proliferate, as well as 
direct stem cell phenotype into the desired tissue type. In this study, we developed an 
osteomimetic PLGA scaffold that allows for hESC attachment, proliferation, and 
differentiation into osteogenic lineage. As previously mentioned, hESCs require surface 
modification in order to be able to attach to 3D substrates. The ECM placed on the 
scaffold can provide signals through proteins interacting with integrins, which in turn 
influences cell phenotype. We hypothesized that native bone ECM deposited by human 
osteoblasts (hOBs) will cover the surface of microsphere-sintered PLGA scaffolds, and 
will direct the differentiation of hESCs into bone lineage by providing a natural bone 
tissue microenvironment. This hypothesis is based on studies demonstrating the use of 
native bone ECM components in stimulating hESCs and hMSCs to differentiate into 
osteoblasts [98, 99]. To this end, the properties of the osteomimetic scaffolds such as 
ECM composition and morphology as well as the in vitro differentiation of hESCs into 
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4.2 Synthesis of PLGA Microsphere-sintered Scaffolds 
Scaffolds with diameters of 10 mm and heights of 2 mm were fabricated and used 
in this study. Briefly, PLGA (75:25 lactide to glycolide ratio) (Lactel Absorbable 
Polymers) was dissolved in dichloromethane (Sigma) to form a 1:4 w/v polymer solution. 
This solution was added to a 1% poly(vinyl alcohol) solution (Sigma) while being stirred 
at 330 rotations per minute (RPM) for 24 hours to allow for adequate evaporation of the 
solvent. After harvesting the microspheres by vacuum filtration, the samples were 
washed with deionized (DI) water and stored at -20°C for 24 hours. The microspheres 
were lyophilized to completely remove all moisture. Commercially available micron 
sieves were used to isolate microspheres of diameter 500-700 μm and they were placed 
into stainless steel molds, heated at 85ºC for 12 hours, and sintered into cylindrical disks. 
 
4.3 Human Osteoblast (hOB) Cell Culture and PLGA Scaffold Seeding 
 P3 human osteoblasts hFOB 1.19 (ATCC) were cultured in osteogenic 
differentiation medium consisting of DMEM/F12 (Gibco), 10% FBS (Atlas), 10 mM β-
glycerophosphate (Sigma), 50 μg/mL ascorbic acid (Sigma), 1 μM dexamethasone 
(Sigma), and 1% penicillin/streptomycin (Invitrogen). Medium was changed every other 
day and cells were passaged once 80% confluency was reached. After two passages, 
hOBs were trypsinized and seeded on the scaffolds. 
Before seeding hOBs on the PLGA substrates, scaffolds were sterilized by 
immersion in 70% ethanol for 10 minutes, washed 3x with phosphate buffered saline 
(PBS), and exposed to UV light for 30 minutes on each side. hOBs were detached from 
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the culture flask using trypsin and 20 μL (containing 5 x 105 cells) of cell suspension 
were seeded per scaffold. Cells were cultured in osteogenic medium for 14 days and 
culture medium was changed every other day. 
Cell attachment and proliferation was analyzed during the 14 day culture period 
using [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS) (Promega) colorimetric assay. 300 μL of fresh media was added to 
each scaffold, and incubated for 2 hours with 60 μL of MTS solution. The resulting 
solution was diluted 1:5 and the absorbance was read at 492 nm using a UV Vis 
Spectrophotometer. 
 
4.4 Decellularization and Analysis 
PLGA scaffolds were decellularized by adding a sterile solution of 0.25% Triton 
X-100 (Sigma) and 0.25% deoxycholate (Alfa Aesar) dissolved in PBS for 30 minutes at 
4°C, followed by incubation at 37°C for several hours. The decellularization solution was 
removed and scaffolds were washed 3x with PBS.  
Decellularized scaffolds were characterized by Alizarin Red S staining, calcium 
quantification, alkaline phosphatase (ALP) staining, collagen II staining, and scanning 
electron microscopy (SEM). To visualize the mineralized ECM, samples were first fixed 
in 10% formalin for 30 minutes and washed 3x with DI water. Alizarin Red S staining 
solution (pH 4.2-4.5) (Alfa Aesar) was added to the samples at a concentration of 0.02 
mg/mL and incubated for 5 minutes. Samples were washed for 5 hours in 100% ethanol 
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and ethanol was changed every 30 minutes. Mineralized ECM was visualized with a 
Zeiss light microscope. To quantify the mineralized calcium, the O cresolphthalein 
complexone (Sigma) method was used. DI water was used to wash the scaffolds 3x, and 
0.6 mol/L hydrochloric acid was employed to homogenize the samples followed by 4 
hours of shaking at 4 °C for calcium extraction. The amount of calcium was determined 
by reading the absorbance at 570 nm with a UV Vis spectrophotometer. Alkaline 
phosphatase was detected by using alkaline phosphatase kit #85 (Sigma) in which 
scaffolds were fixed with 10% formalin for 30 minutes and washed 3x with PBS. The 
Fast Blue capsule was dissolved in napthanol to prepare the staining solution, added to 
the scaffold, and incubated for 30 minutes. The scaffolds were washed 3x with PBS 
followed by incubation in the Mayer’s Hematoxylin solution for 10 minutes. ALP was 
observed and photographed using a Nikon E600 light microscope. To determine collagen 
II expression, scaffolds were fixed in 10% formalin for 30 minutes and washed 3x with 
PBS. After washing, scaffolds were permeabilized using 0.1% Triton X-100 solution for 
15 minutes. Cells were washed 3x with PBS and blocked using 1% bovine serum 
albumin (BSA) (Sigma) in PBS for 30 minutes. FITC-conjugated anti-collagen II 
antibody (1:100) (Thermo) was added to the scaffolds for 1 hour followed by washing 3x 
with PBS. Cell nuclei were stained by adding 4’-6-diamidino-2-phenylindole (1:25) 
(DAPI) (Sigma) antifade to the decellularized constructs. The samples were visualized 
using a Zeiss 510 LSM confocal microscope and a water immersion lens. For SEM 
analysis, cells on the scaffolds were fixed in 1% glutaraldehyde for 1 hour followed by 
fixation in 3% glutaraldehyde at 4°C overnight. The scaffolds were dehydrated 
sequentially by a series of increasing ethanol concentrations (10, 30, 50, 70, 90, 95, 95, 
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100, 100%) for 15 minutes each. PGLA scaffolds were dried overnight and coated with 
gold/palladium. Scaffolds were observed under Zeiss Ultra Plus FESEM after coating. 
 
4.5 hESC Seeding 
hESCs from cell line h9 (Wicell) p38 were grown on a feeder layer of mitomycin 
C inactivated mouse embryonic fibroblasts (cell line PMEF-CFL) (Millipore) in medium 
consisting of DMEM/F12 (Gibco), 20% Knock-out serum replacement (Gibco), 3.5 mM 
L-Glutamine (Invitrogen), 100 μM β-mercaptoethanol (Sigma), 1% non-essential amino 
acids (Invitrogen), and 10 ng/mL bFGF (Peprotech). The PMEF cell line was used as a 
feeder layer and cultured in high glucose with L-glutamine DMEM (Gibco) 
supplemented with 10% FBS and 1% penicillin/streptomycin (Invitrogen). Mitomycin C 
(10 mg/mL) (Sigma) was used to inactivate PMEF cells for 2.5 hours, after which cells 
were seeded at a density of 2.1 x 104 cells/cm2 on tissue culture plastic coated with 1% 
gelatin (Sigma). Cells were cultured for 1 day in PMEF media prior to hESC seeding. 
hESCs were detached from the tissue culture plate by a combination of the enzyme 
collagenase IV (Sigma) and by manually scraping.  Approximately 50,000 hESCs were 
seeded per scaffold, and conditioned medium was used to ensure cell attachment 
overnight. The following day, culture medium was changed from conditioned medium to 
osteogenic differentiation medium. Osteogenic differentiation medium was changed the 
following day to remove cell debris, then every 3 days for the remainder of the 
experiment. 
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For the control groups, two dimensional (2D) tissue culture polystyrene (TCPS) 
and Geltrex-coated PLGA scaffolds were used. To coat the PLGA scaffolds and 2D 
culture plates, 2.5 μL of Geltrex (Invitrogen) was mixed with 1 mL of cold DMEM/F12, 
added to the scaffolds and plates, and incubated at 37°C for 1 hour, then incubated at 
room temperature for 1 hour. Approximately 50,000 hESCs were seeded per well of a 24-
well plate, and per Geltrex-coated PLGA scaffold. 
 
4.6 Cell Attachment, Growth, and Morphology 
At predetermined time points, cell morphology was assessed using SEM. Cells on 
the scaffolds were prepared as previously described and observed under a Zeiss Ultra 
Plus FESEM after coating. 
 Cell proliferation on scaffolds was assessed using [3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) (Promega) 
colorimetric assay. 300 μL of fresh media was added to each scaffold, and incubated for 2 
hours with 60 μL of MTS solution. The resulting solution was diluted 1:5 and the 
absorbance was read at 492 nm using a UV Vis Spectrophotometer. 
 Cytoskeleton formation was observed by F-actin staining. Cells on the scaffolds 
were fixed at room temperature in 10% formalin for 30 minutes. After washing scaffolds 
3x with PBS, cells were permeabilized using a 0.1% Triton X-100 solution for 15 
minutes. Cells were then washed 3x with PBS and blocked using 4% Goat Serum in PBS 
for 30 minutes. TRITC-conjugated phalloidin (1:40) (Invitrogen) was added to the 
scaffolds for 1 hour, samples were washed 3x with PBS, and cell nuclei were stained with 
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4’-6-diamidino-2-phenylindole (1:25) (DAPI) (Sigma). Stained cells were visualized 
using a Zeiss 510 LSM confocal microscope under a water immersion lens. 
 
4.7 Assessment of Osteogenic Differentiation 
Osteogenic differentiation was assessed by monitoring the calcium deposition, 
osteocalcin expression, and qRT-PCR analysis of RUNX2 and BGLAP genes. 
Calcium was quantified using the O cresolphthalein complexone (Sigma) method. At 
predetermined time points, cell culture medium was removed from the scaffolds and cells 
were washed 3x with DI water. 0.6 mol/L hydrochloric acid was used to homogenize the 
samples followed by 4 hours of shaking at 4 °C for calcium extraction. Samples were 
compared against CaCl2 standards and the amount of calcium was determined by reading 
the absorbance at 570 nm with a UV Vis spectrophotometer. 
ECM mineralization was assessed using Alizarin Red S staining. Samples were fixed 
in 10% formalin for 30 minutes and washed 3x with DI water. Alizarin Red S staining 
solution  
(pH 4.2-4.5) (Alfa Aesar) was added to the samples at a concentration of 0.02 mg/mL and 
incubated for 5 minutes. Samples were washed for 5 hours in 100% ethanol, and ethanol 
was changed every 30 minutes. Mineralized ECM was visualized with a Nikon E600 
light microscope.  
Osteocalcin was qualitatively observed by immunofluorescence staining. In brief, 
cells were fixed in 10% formalin for 30 minutes, followed by washing 2x with a rinse 
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buffer (20 mM Tris-HCL and 0.05% Tween- 20 in PBS) (Sigma). The sample was then 
permeabilized with 0.1% Triton X-100 (Sigma) in PBS for 15 minutes, and washed 2x 
with the rinse buffer. Cells were blocked with 4% goat serum in PBS for 30 minutes. The 
primary antibody, osteocalcin (1:50) (R&D Systems), was added to the scaffolds and 
incubated for 60 minutes. Following the primary antibody incubation, the samples were 
washed 3x with the rinse buffer for 5 minutes each time. Then Alexafluor 594 (1:1000) 
(Invitrogen) was added to the samples and incubated for 1 hour, followed by 4’-6-
diamidino-2-phenylindole (1:25) (DAPI) (Sigma) nuclear stain. Stained cells were 
visualized using a Zeiss 510 LSM confocal microscope under a water immersion lens. 
Total RNA was extracted from the samples using the GeneJET RNA Purification Kit 
(Thermo Scientific). One μg of RNA was used as a template for single-strand cDNA 
synthesis with the RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific). In 
brief, RNA was prepared by first removing genomic DNA from the sample. The reaction 
buffer with MgCl2, DNase I, and nuclease-free water was added to 1 μg of RNA to a total 
volume of 10 μL. The sample was incubated at 37 °C for 30 minutes, then 1 μL 50 mM 
EDTA was added and incubated at 65 °C for 10 minutes. The template RNA was mixed 
with 1 μL oligo (dT)18 primer and nuclease-free water to a volume of 12 μL, followed by 
the addition of 4 μL of 5x Reaction Buffer, 1 μL Ribolock RNase Inhibitor, 2 μL 10 mM 
dNTP Mix, and 1 μL RevertAid M-MuLV Reverse Transcriptase. This mixture was then 
incubated at 42 °C for 1 hour. The SensiFAST SYBR No-ROX Kit (Bioline) was used 
for qPCR. 100 ng of cDNA was mixed with 10 μL 2x SensiFAST SYBR No-ROX Mix, 
10 μM forward primer, 10 μM reverse primer, (see Table 1 for sequences) and nuclease-
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free water to 20 μL. A 3-step cycling was used on a Bio-Rad CFX96 instrument: 1 cycle 
of 95 °C for 2 minutes to activate the polymerase, followed by 40 cycles of 95 °C for 5s 
to denature, 65 °C for 10s for annealing, then 10s at 72 °C for extension.  Gene 
expression of RUNX2 and BGLAP were normalized to GAPDH and presented as relative 
values. 
 
4.8 Statistical Analysis 
Three samples (n=3) were analyzed per condition unless otherwise stated. Error bars in 
graphs represent mean ± standard deviation (SD). One-way analysis of variance (one-way 
ANOVA) was used to determine statistical significance. Comparison between the two 




Figure 4.1 demonstrates the growth of hOBs on PLGA scaffolds during the 14 day 
culture period. The number of cells was determined for days 1, 4, 7, and 14. Cells 
attached to the scaffolds and cell number steadily increased at each sequential time point. 
From this assay it was confirmed that cells were proliferating, therefore depositing ECM 
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Table 4.1 Primer sequences used in qRT-PCR to analyze osteogenic differentiation of 
hESCs on osteomimetic PLGA. 
Primer Name Sequence 
RUNX2 Forward 5’-CTC ACT ACC ACA CCT ACC TG-3’ 
RUNX2 Reverse 5’-TCA ATA TGG TCG CCA AAC AGA TTC-3’ 
BGLAP Forward 5’-GGC GCT ACC TGT ATC AAT GG-3’ 
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Figure 4.2 shows characterization of the microsphere-sintered PLGA scaffolds. The 
scaffolds were all highly porous with interconnected structures, and demonstrated similar 
architecture to that of trabecular bone. SEM images of decellularized scaffolds (Figure 
4.2A) showed ECM deposition covering the surface of the microspheres, with collagen 
fibrils clearly defined. Alizarin Red S staining indicated the presence of calcium in the 
mineralized ECM (Figure 4.2B), while collagen II staining demonstrated the presence of 
collagen II in the ECM (Figure 4.2C). The enzyme ALP was also found on the surface of 
the decellularized PLGA scaffolds, as shown by the purple/blue stain indicative of ALP 
(Figure 4.2D). The quantification of the mineralized calcium on the decellularized 
scaffolds indicated that an average of 1.17 μg of calcium was present per construct.  
Figure 4.3 demonstrates cell attachment and morphology of hESCs (Figure 4.3A), 
and proliferation and morphology of hESC-derived osteogenic progenitors (Figure 4.3B). 
The hESC colonies were able to attach to the decellularized matrix, initially in large, 
compact colonies (Figure 4.3A). They continued to grow and spread, and after 7 days the 
cells no longer exhibited an undifferentiated hESC phenotype (Figure 4.3B). The cells 
formed bridges between microspheres and fully covered the scaffold surface at day 35 
(Figures 4.3C and 4.3D). Cell proliferation was monitored by the MTS assay, and in all 
conditions, cells increased in number (Figure 4.4). Interestingly, the decellularized 
scaffold group had the highest cell numbers compared to the Geltrex-coated PLGA 
group, with the exception of day 7. Cytoskeleton organization and morphology was 
observed by SEM and immunofluorescence staining of F-actin and DAPI (Figure 4.5A  
 
 













Figure 4.1 Proliferation of hOBs on PLGA scaffolds at time points of day 1, day 4, 
day 7, and day 14. Cell number steadily increased during the 14 day culture period. 
# represents a significant difference in cell number between day 14 and day 1 at a 














Figure 4.2 Analysis of osteomimetic scaffolds. (A) SEM image of ECM covering 
surface of PLGA scaffold, scale bar 10 μm and magnification 2000x; (B) Alizarin 
Red S staining of calcium depostited by hOBs on scaffold surface, scale bar 200 μm 
and magnification 10x; (C) Collagen II staining of ECM confirms ECM composition, 
scale bar 50 μm and magnification 20x; (D) ALP staining of ECM covering surface of 
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and 4.5B, respectively). We observed that the cells proliferated on the surface of the 
scaffolds and within the pores, and there was no noticeable variation in cytoskeleton 
structure and morphology among the groups. 
Osteogenic differentiation was assessed by observing calcium content, osteocalcin 
expression, and qRT-PCR to quantify osteogenic marker genes. The highest level of 
calcium content was expressed by the hESCs on the decellularized scaffolds, followed by 
the Geltrex-coated PLGA group, with the 2D TCPS group demonstrating the least 
amount of mineralized matrix (Figure 4.6A). The immunofluorescence staining of the 
differentiated cells on the scaffolds showed that osteocalcin was present in the 
differentiated hESCs on the decellularized scaffolds, Geltrex-coated PLGA scaffolds, and 
2D TCPS. The highest level of osteocalcin was detected in the decellularized scaffold, as 
shown in figure 4.5C. In order to quantitatively evaluate the marker genes indicative of 
osteogenic differentiation, qRT-PCR was employed. It was found that the decellularized 
scaffolds as well as the PLGA scaffolds exhibited the highest expression of RUNX2 as 
compared to the 2D culture plate (Figure 4.6B). BGLAP levels were the highest in 
decellularized scaffolds, followed by the PLGA scaffolds and 2D TCPS (Figure 4.6C). 
 
 




Figure 4.3 SEM images of hESCs and hESC-derived osteogenic progenitors on 
osteomimetic scaffolds. (A) Day 0 shows colony attachment, indicated by white 
arrow, scale bar 100 μm and magnification 300x; (B) Day 7 demonstrates the onset of 
differentiation, scale bar 10 μm and magnification 500x; (C) Day 35 shows 
differentiated cells with osteoblast-like morphology, scale bar 100 μm and 


















Figure 4.4 Proliferation of hESCs on Geltrex-coated PLGA and osteomimetic 
scaffolds, shown as cell number/scaffold. * and + represent significant difference in 
cell number between the Geltrex-coated PLGA and the osteomimetic scaffolds at 












Figure 4.5 Confocal images of day 35 differentiated hESCs on osteomimetic 
PLGA, scale bars 50 μm and magnification 20x. (A) Actin demonstrates 
cytoskeleton formation; (B) DAPI shows nuclear staining; (C) Osteocalcin 













Figure 4.6 Calcium deposition and gene expression of differentiated hESCs on 2D 
culture plates, Geltrex-coated PLGA, and osteomimetic PLGA. *, +, and ^ 
represents significant difference in calcium content and gene expression by cells 
on osteomimetic scaffolds compared to Geltrex-coated PLGA and 2D tissue 
culture plates at significance levels of p<0.05, 0.1, and 0.5, respectively. (A) 
Calcium quantification for each group represented as μg/substrate where the 
substrate is the scaffold for the osteomimetic PLGA and geltrex-coated PLGA 
groups, and the 2D well surface for the TCPS group; (B) Relative RUNX2 gene 
expression (n=2); (C) Relative BGLAP gene expression (n=2). All values were 
normalized to GAPDH. 
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4.10 Discussion 
The ability to develop a 3D porous scaffold with comparable mechanical and 
structural properties to that of natural bone governs the success of many bone tissue 
engineering endeavors. Bone is a complex tissue composed of an architectural hierarchy: 
(i) the macrostructure which is made up of cortical and cancellous bone, (ii) the 
microstructure which is composed of osteons, haversian systems, and trabeculae, (iii) the 
submicrostructure which is comprised of the lamellae, (iv) the nanostructure which is 
predominately composed of collagen I fibers, and (v) the sub-nanostructure made up of 
mineralized matrix, smaller collagen subunits, and other organic proteins [15]. Due to 
this intricate tissue configuration, recreating bone structure is a major hurdle in 
generating scaffolds. Another obstacle in bone tissue engineering studies is deciphering 
specific roles of scaffold design parameters governing in vitro osteogenic differentiation 
and in vivo osteointegration.  
 The research work described in this study centers in on designing an osteomimetic 
scaffold composed of microsphere-sintered PLGA scaffolds and native bone ECM 
components secreted by osteoblast cells. These scaffolds were then applied to an in vitro 
study that analyzed the osteogenic differentiation of hESCs seeded on these 
decellularized scaffolds as compared to the control Geltrex-coated PLGA scaffolds and 
2D tissue culture polystyrene group. It was hypothesized that hESCs seeded on the native 
bone ECM scaffolds would exhibit faster osteogenic differentiation as well as greater 
expression of mineralized matrix, higher levels of osteocalcin expression, and greater 
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levels of bone marker genes such as RUNX2 and osteocalcin. A rationale for this work 
was based off of recent studies that demonstrated the potential of decellularized bone 
matrices in directing the differentiation of hESCs and hMSCs into osteogenic lineage [98, 
99]. 
In this study, we used microsphere-sintering to develop scaffolds. This fabrication 
technique produces scaffolds of tunable porosity and mechanical strength within the 
range of trabecular bone [276, 283]. Osteoblasts readily attach to PLGA substrates 
through proteins in the FBS adsorbing to the surface of scaffolds allowing for integrin-
ligand interactions, however hESCs need surface modifications in order to adhere to the 
scaffolds. To alter the surface of the substrate for promoting the attachment of hESCs, a 
native bone microenvironment was generated by seeding hOBs on the PLGA scaffolds, 
then removing the cells while leaving the ECM intact. During the 14 day culture period, 
hOBs proliferated on the scaffolds and deposited ECM on the surface of the substrate. 
The ECM secreted by the osteoblasts contained calcium, alkaline phosphatase, collagen 
II, and other proteins found in bone structure. Since bone is formed via endochondral 
ossification in the embryo, the collagen II structure laid down by the hOBs is thought to 
stimulate the natural signaling pathways for hESCs to differentiate into osteogenic 
lineage [284]. 
Cell attachment and morphology was assessed by using SEM. Cell shape is indicative 
of adhesion since cells that have a spread-out morphology have more focal adhesions and 
greater cell-substrate contact than cells exhibiting a round morphology. Differentiated 
hESCs on the Geltrex-coated PLGA scaffold and decellularized PLGA scaffold 
demonstrated a spread phenotype, and the cells were able to migrate throughout the 
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scaffold by forming extensions between adjacent microspheres. This result is consistent 
with previous studies demonstrating the proliferation of primary fibroblasts and 
osteoblasts on PLGA microsphere-sintered scaffolds [276, 283, 285]. 
In line with other studies, our in vitro evaluation of the decellularized scaffolds 
demonstrated a higher level of osteogenic differentiation as compared to the control 
groups. hESCs underwent differentiation over a 35 day period as a result of physical cues 
from the native ECM scaffolds and chemical growth factors in the differentiation media. 
The extent of differentiation was measured by quantifying calcium expression, as well as 
immunofluorescence staining of osteocalcin and by analyzing gene expression of 
osteocalcin and RUNX2 by qRT-PCR. Common methods of analyzing osteogenic 
differentiation include quantifying alkaline phosphatase, collagen I, non-collagenous 
proteins such as osteocalcin, and the existence of bone apatite [286]; however these 
qualities are not unique to bone-forming osteoblasts. The most stand-alone method of 
determining osteoblast differentiation besides analyzing mRNA is the observation of a 
cell-mediated calcified extracellular matrix [287]. We determined calcium content of 
each experimental group, and the osteomimetic scaffolds expressed the highest amount as 
compared to the 2D control and Geltrex-coated PLGA scaffolds.  Our study showed that 
3D microenvironments produced from microsphere-sintered PLGA scaffolds generates a 
higher level of hESC differentiation into osteogenic lineage as compared to cells grown 
on 2D tissue culture plates. Furthermore, our results from these tests demonstrate that the 
presence of native bone ECM on 3D PLGA scaffolds leads to an elevated expression of 
osteogenic markers. RUNX2 is the main transcription factor for the osteoblast, and it is 
exclusively required for osteoblast differentiation [97]. RUNX2 expression determines 
 
 56   
osteogenic lineage commitment, therefore the upregulation of RUNX2 mRNA quantified 
by qRT-PCR demonstrates the differentiation of hESCs into osteoblasts. 
The advantage of our synthetic scaffolds coated with bone ECM is that we can design 
the polymer to mimic the structure of trabecular bone while exhibiting similar mechanical 
properties. This eliminates the risk of immunogenicity associated with using bone from 
humans or animals that has been decellularized. Decellularized scaffolds offer a native 
bone microenvironment in which stem cells can receive signals from the proteins and 
embedded growth factors. These signals govern cell type and function. 
The enthusiasm for using hESCs as a source for bone tissue is hindered by ethical 
concerns as well as the need to establish protocols to obtain a homogenous population of 
differentiated cells [83, 288]. Also, the risk of teratoma formation is a major issue in 
using hESCs in vivo [289, 290]. Future directions of this study include delineating the 
mechanisms by which native bone ECM components and architecture modulates the 
osteogenic differentiation of hESCs. This will enable us to design a scaffold that induces 
cells to exclusively form components of bone and it will ensure that teratoma formation 
will not occur.  
 
4.11 Conclusions 
In this study, osteomimetic PLGA scaffolds were fabricated by microsphere-sintering 
and by utilizing hOBs to deposit bone ECM on the surface of the polymer. The native 
bone ECM substrates resembled bone tissue in composition. The potential of these 
scaffolds as bone graft substitutes was evaluated by the in vitro differentiation of hESCs 
on the osteomimetic substrates as well as Geltrex-coated PLGA and 2D tissue culture 
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plates. Our results demonstrated that the decellularized scaffolds promoted cell adhesion, 
proliferation, and osteogenic differentiation. Incorporating native components of bone-
ECM with PLGA scaffolds has proven to be a successful approach to tissue engineering 
bone. A more detailed study is warranted to parse the in vivo mechanisms by which ECM 



















CHAPTER 5: RESVERATROL AS A STIMULATOR OF OSTEOGENESIS AND 
MODULATOR OF INFLAMMATION 
 
5.1: Introduction 
Tissue engineering offers a revolutionary approach to restore bone tissue and heal 
critical-size defects resulting from trauma, infection, tumor resection or other 
musculoskeletal diseases [1]. This is traditionally accomplished by utilizing a 
combination of biomaterials, cells, and signaling factors. Biomaterials provide a three-
dimensional substrate with specific engineered characteristics for cells to attach and 
proliferate. Growth factors supply essential signaling cues for cells to migrate and 
differentiate into the desired tissue type. Cells seeded on 3D biomaterials contribute to 
the healing process through signaling events that guide newly formed tissue integration 
with the host tissue. 
The success of tissue engineering strategies is contingent on the ability of blood 
vessels to form within the scaffolds and supply nutrients to the transplanted cells [291]. 
This process is controlled through a cascade of events that are mediated by chemotaxis 
and the host inflammatory response. Inflammation is the process by which the body 
protects itself from intruders, and if left uncontrolled, potentially interferes with the 
integration of implanted biomaterials. The complicated interplay of immune cells and 
signaling molecules at the interface of an implanted engineered graft must be parsed in 
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order to effectively design a method to harness host inflammation to promote wound 
healing.  
As mentioned in Chapter 1, Section 3, the body responds to an implanted 
biomaterial with a critical sequence of the host immune reactions. The host inflammatory 
response is commonly initiated when native vasculature is disrupted, and the release of 
serum proteins from the vasculature adsorb to the implanted biomaterial surface. This 
forms the provisional matrix composed of fibrin, platelet granule components such as 
thrombospondin, TGF-α, TGF-β, PDGF, PF4, and ECGF1 [28]. Monocytes exit the 
capillaries, differentiate into pro-inflammatory M1 macrophages, and attach to the 
provisional matrix. The secretion of cytokines such as TNF-α, IL-1β, IL-6, and MCP-1 
drives the acute inflammation response [29, 30]. Following the acute inflammatory 
response, chronic inflammation manifests at the biomaterial-host interface. This is 
defined by the presence of macrophages, monocytes, lymphocytes, blood vessel 
proliferation, and connective tissue formation [31-34]. Foreign body giant cells and 
macrophages will exist at tissue-implant interface for the duration of the biomaterial’s 
lifetime [35-39]. A fibrous capsule forms as a result, separating the biomaterial from the 
host tissue [28]. In some tissue types, acute inflammation stimulates M1 pro-
inflammatory macrophages to change phenotype into wound healing M2 macrophages. 
The polarization of M1 to M2 is a critical component of attenuating graft and biomaterial 
rejection.  
Several strategies have been designed to mediate the host inflammation in 
response to biomaterials. In one approach, a hydrophilic boundary between implant and 
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host tissue [40, 41] was created to enhance the biocompatibility of implants [42-44]. In 
another approach, anti-inflammatory biomolecules were utilized to inhibit the secretion 
of mediators such as leukotrienes and prostaglandins, and delay fibroblast capsule 
formation [52]. A major drawback of this method is the numerous undesired systemic 
side effects [53]. For example, anti-inflammatory corticosteroid based drugs inhibit new 
blood vessel formation necessary for nutrient exchange in the implanted tissue [54, 55]. 
Another commonly used method is the induction of angiogenesis based on the use of 
growth factors [46-48]. Despite its limited success, this method can overexpose tissues to 
growth factors leading to arthritis and tumor formation [49-51].  
Efforts to identify compounds with anti-inflammation properties have led to 
discovery of resveratrol, a polyphenol found in the skin of grapes [292, 293]. Strikingly, 
this molecule has been shown to exhibit therapeutic effects in a number of diseases 
including cancer, cardiovascular failure, viral infections, neurodegeneration, and 
ischemic injuries [294-304]. The exact mechanisms by which resveratrol impacts 
inflammation is under intense investigation. Suppression of transcription factor nuclear 
factor kappa B (NF-κB), TNF-α and interleukin-1 (IL-1), prostaglandin E2 (PGE2), and 
nitric oxide (NO) synthesis have demonstrated to be potential means by which resveratrol 
attenuates inflammation [305-307]. Further studies are warranted to explore the signaling 
cascades governing the anti-inflammatory potential of resveratrol in the context of wound 
healing and implant integration. 
In addition to its anti-inflammatory characteristic, resveratrol has been found to 
possess pro-osteogenic properties. Augmentation of the canonical Wnt signaling 
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pathway, activation of sirtuin 1 (SIRT-1), and acetylation of runt-related transcription 
factor 2 (RUNX2) have been shown to be the underlying mechanism behind the 
induction of osteogenesis in stem cells by resveratrol [308-311]. Additionally, reports of 
the bone inductive effects of resveratrol through the activation of estrogen receptor have 
highlighted this natural compound as a viable candidate factor for bone tissue engineering 
applications. 
The main objective of this study is to determine the potential of resveratrol to 
lessen inflammation and stimulate hMSCs towards bone lineage in 2D culture systems. 
The hypothesis behind our effort is that resveratrol can be utilized to (i) induce the 
osteogenic differentiation of hMSCs, and (ii) switch macrophage polarization from a pro-
inflammatory M1 to a wound healing M2 phenotype. We tried this hypothesis by 
assessing the time-dependent effect of varying resveratrol doses on macrophage gene 
expression as well as hMSCs osteogenic differentiation in 2D culture systems. The  
approach developed in this study has the potential to be applied to 3D scaffold design for 
harnessing inflammation and promoting bone tissue formation. 
 
5.2: Human Monocyte Cell Culture 
Human THP-1 monocytes (sigma) were cultured in basal medium consisting of 
RPMI 1640 (Sigma), 2 mM L-Glutamine (Gibco), 10% FBS (Atlas), and 1% 
penicillin/streptomycin (Invitrogen). Medium was changed every other day, and cells 
were kept at a density of 3-8 x 106 cells/mL in order to maintain growth. THP-1 
monocytes were seeded in each well of a 24 well plate at a number of 500,000 cells per 
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well. Depending on the experimental conditions, cells were kept at an undifferentiated 
state, were differentiated to M0 macrophages, or were differentiated to M1 macrophages. 
 
5.3: Differentiation of Monocytes to Macrophages 
THP-1 monocytes were differentiated to M0 macrophages by adding 200 nM 
phorbol 12-myristate 13-acetate (PMA) to the basal medium for 24 hours after which 
cells adhered to the tissue culture plate. To differentiate M0 macrophages to M1 
macrophages, basal medium supplemented with 1 μg/mL LPS (Sigma) and 20 ng/mL 
recombinant interferon gamma (IFNγ) (Peprotech) was added to the wells for 24 hours. 
Differentiation of M0 macrophages to M2 macrophages was accomplished by adding 20 
ng/mL recombinant interleukin 4 (IL-4) (Peprotech) as well as 20 ng/mL recombinant 
interleukin-13 (IL-13) (Peprotech) to the basal medium, and then culturing M0 
macrophages in the differentiation medium for 18 hours. 
 
5.4: Effect of Resveratrol on M1 Macrophages 
Resveratrol was added to basal THP-1 monocytes culture medium at concentrations 
of 1 μM, 10 μM, and 25 μM, and gene expression of cytokines VEGF, TNF-α, IL-6, 
macrophage mannose receptor 1 (MRC-1), and interleukin 10 (IL-10) were analyzed 
using qRT-PCR after resveratrol exposure durations of 2 and 5 days.  
The total RNA was extracted and purified from the samples using the GeneJET RNA 
Purification Kit (Thermo Scientific). Briefly, RNA (0.5 μg) was prepared as a template 
for single-strand cDNA synthesis using the RevertAid First Strand cDNA Synthesis Kit 
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(Thermo Scientific). First, genomic DNA was removed from the RNA sample by 
applying a mixture of the supplied reaction buffer with MgCl2, DNase I, and nuclease-
free water to a total volume of 10 μL. The samples were then incubated at 37 °C for 30 
minutes, after which 1 μL 50 mM EDTA was added. The samples were placed in a 65 °C 
water bath for 10 minutes. The template RNA was mixed with 1 μL oligo (dT)18 primer 
and nuclease-free water to a volume of 12 μL, followed by the addition of 4 μL of 5x 
Reaction Buffer, 1 μL Ribolock RNase Inhibitor, 2 μL 10 mM dNTP Mix, and 1 μL 
RevertAid M-MuLV Reverse Transcriptase. This mixture was incubated at 42 °C for 1 
hour in a Bio-Rad CFX96 thermocycler instrument. To detect gene expression, the 
SensiFAST SYBR No-ROX Kit (Bioline) was used for qPCR. Briefly, 100 ng of cDNA 
was mixed with 10 μL 2x SensiFAST SYBR No-ROX Mix, 10 μM forward primer, 10 
μM reverse primer, (see Table 5.1 for primer sequences, Integrated DNA Technologies) 
and nuclease-free water to 20 μL. A 3-step cycling was used on a Bio-Rad CFX96 
instrument: 1 cycle of 95 °C for 2 minutes to activate the polymerase, followed by 40 
cycles of 95 °C for 5s to denature, 65 °C for 10s for annealing, and  10s at 72 °C for 
extension. Gene expression of VEGF, TNF-α, IL-6 MRC-1, and IL-10 were normalized 
to GAPDH and presented as relative values. 
 
5.5: Human Mesenchymal Stem Cell Culture and Osteogenic Differentiation with 
Resveratrol 
Human mesenchymal stem cells were cultured in a basal medium consisting of 
DMEM/F12 (Gibco), 10% FBS (Atlas), and 1% penicillin/streptomycin (Invitrogen).  
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Table 5.1. Primers used for quantitative real-time polymerase chain reaction to 
demonstrate macrophage phenotype and hMSC differentiation. 
 
Gene 5’-3’ primer sequences: (F: forward R: reverse) 
VEGF-A 
F: ATC TGC ATG GTG ATG TTG GA 
R: GGG CAG AAT CAT CAC GAA GT 
IL-10 
F: GTG ATG CCC CAA GCT GAG A 
R: CAC GGC CTT GCT CTT GTT TT 
TNF-α 
F: CTG CTG CAC TTT GGA GTG AT 
R: AGA TGA TCT GAC TGC CTG GG 
MRC-1 
F: CAG CGC TTG TGA TCT TCA TT 
R: TAC CCC TGC TCC TGG TTT TT 
IL-6 
F:AGC CAC TCA CCT CTT CAG AAC 
R: GCC TCT TTG CTG CTT TCA CAC 
BGLAP 
F: GGC GCT ACC TGT ATC AAT GG 
R: TCA GCC AAC TCG TCA CAG TC 
RUNX2 
F: CTC ACT ACC ACA CCT ACC TG 
R: TCA ATA TGG TCG CCA AAC AGA TTC 
GAPDH 
F: GTG GAC CTG ACC TGC CGT CT 
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Medium was changed every 5 days and cells were passaged once 80% confluency was 
reached. 
To study the impact of resveratrol on osteogenic differentiation, hMSCs were 
seeded in a 24 well plate (50,000 cells/well) for 24 h after which the culture medium was 
changed. Four conditions were considered in this study: basal medium (negative control), 
basal medium supplemented with 12.5 μM resveratrol (Sigma), osteogenic medium, or 
osteogenic medium supplemented with 12.5 μM resveratrol. Growth media was 
exchanged 3 times per week for all groups.  
 
5.6: Analysis of hMSC Proliferation and Osteogenic Differentiation 
Samples were characterized by MTS proliferation assay, osteocalcin 
immunofluorescence staining, Alizarin Red S staining, calcium quantification, alkaline 
phosphatase (ALP) staining, and ALP quantification.  
Cell proliferation was monitored using [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) (Promega) 
colorimetric assay. Fresh media was added to each well at a volume of 100 μL, and 
incubated for 4 hours with 20 μL of MTS solution. The resulting solution was diluted 1:5 
and the absorbance was read at 492 nm using a Biotek Synergy 2 plate reader. 
Osteocalcin was qualitatively assessed using immunofluorescence staining. Cells 
were fixed in 10% formalin for 30 minutes, followed by washing with a rinse buffer (2x) 
(20 mM Tris-HCL and 0.05% Tween- 20 in PBS) (Sigma). The samples were 
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permeabilized with 0.1% Triton X-100 (Sigma) in PBS for 15 minutes. Cells were 
washed 2x with the rinse buffer, and blocked with 4% goat serum in PBS for 30 minutes. 
The primary antibody, osteocalcin (1:50) (R&D Systems), was added to the samples and 
incubated overnight at 4°C. Following the primary antibody incubation, the cells were 
washed 3x with the rinse buffer for 5 minutes each time. Then Alexafluor 594 (1:1000) 
(Invitrogen) was added to the samples and incubated for 1 hour at room temperature, 
followed by 4’-6-diamidino-2-phenylindole (1:25) (DAPI) (Sigma) nuclear stain. Images 
of stained cells were obtained using a Nikon Eclipse 80i with NIS-Elements imaging 
software. 
 To visualize the mineralized calcium, samples were fixed in 10% formalin for 30 
minutes and washed 3x with DI water. Alizarin Red S staining solution (pH 4.2-4.5) 
(Alfa Aesar) was added to the samples at a concentration of 0.02 mg/mL and incubated 
for 5 minutes. Samples were washed for 6 hours in 100% ethanol as ethanol wash 
solution was changed every 30 minutes. Mineralized ECM was imaged with a Nikon 
E600 light microscope. To quantify the mineralized calcium, the O cresolphthalein 
complexone (Sigma kit #MAK022) method was employed. The scaffolds were washed 
with deionized (DI) water 3x followed by the use of 0.6 mol/L hydrochloric acid to 
homogenize the samples and 4 hours of shaking at 4°C for total calcium extraction. Each 
sample was added to individual wells of a 96 well plate at a volume of 50 μL, and 90 μL 
of the supplied chromogenic reagent was placed in each well containing the samples. 
After mixing gently, a total of 60 μL of calcium assay buffer was added to each well and 
carefully merged with the other components. The reaction was incubated for 10 minutes 
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in the dark, and the amount of calcium was determined by reading the absorbance at 575 
nm with a Biotek Synergy 2 plate reader.  
ALP expression was quantified using a Bio-Rad Alkaline Phosphatase Substrate 
Kit (#172-1063). Briefly, cells were washed 3x with PBS, then lysed using 0.1% Triton 
X-100 (Sigma) in PBS for 15 minutes at 4 °C. The substrate solution was reconstituted 
by mixing 1 mL of 5x diethanolamine buffer with 4 mL DI water, then dissolving 1 tablet 
of 5 mg p-nitrophenylphosphate in the buffer mixture. Each sample was placed in 
individual wells of a 12 well plate at a volume of 400 μL. A total of 100 μL substrate 
solution was added to the samples and incubated at 37 °C for 30 minutes in the dark after 
which 100 μL 0.4 M NaOH to stop the reaction. The absorbance was read at 405 nm 
using a Biotek Synergy 2 plate reader. ALP was quantitatively detected by using alkaline 
phosphatase kit #85 (Sigma) in which scaffolds were fixed with 10% formalin for 30 
minutes and washed 3x with PBS. The Fast Blue capsule was dissolved in napthanol to 
prepare the staining solution, added to the scaffold, and incubated for 30 minutes. The 
scaffolds were washed 3x with PBS followed by incubation in the Mayer’s Hematoxylin 
solution for 10 minutes. ALP was observed and imaged using a Nikon E600 light 
microscope.  
 
5.7: Resveratrol Modulates Inflammation by Inducing Macrophage Phenotypic Switch 
Figure 5.1 shows the dose dependent effects of resveratrol on M1 macrophages. 
Analysis of inflammatory gene (IL-6, TNF-α) and anti-inflammatory gene (VEGF, MRC-
1 and IL-10) expression by qRT-PCR demonstrated that resveratrol modulates 
 
 68   
inflammation and promotes anti-inflammatory cytokine expression. Inflammatory marker 
IL-6 was significantly lowered with the addition of 10 μM and 25 μM resveratrol at day 
2, and reduced equally by all concentrations of resveratrol by day 5 (Figure 5.1A). 
Consistently, TNF-α was greatly reduced at the 2 day time point by 25 μM of resveratrol. 
Day 5 showed a dose dependent trend of lowered TNF-α expression, with a statistically 
significant reduced inflammatory cytokine level expressed in the 25 μM resveratrol 
containing group (Figure 5.1B). The expression of anti-inflammatory marker IL-10 
significantly increased at the 2 day and 5 day time points with the addition of 25 μM 
resveratrol (Figure 5.1C). Similarly, VEGF expression increased with the addition of 
resveratrol, and day 2 expression showed statistically significant levels in the 1 μM group 
as compared to the control (Figure 5.1D). By day 5, VEGF levels were the greatest with 
M1 macrophages cultured with 25 μM, followed by 10 μM and 1 μM. In line with these 
results, MRC-1 levels were statistically significant for the M1 macrophages cultured with 
25 μM resveratrol at both time points, as compared to the control group (Figure 5.1E). 
 
5.8: Resveratrol Drives the Osteogenic Differentiation of hMSCs 
Figure 5.2 demonstrates the effect of resveratrol on the osteogenic stimulation of 
hMSCs. Cells were cultured in basal hMSC medium, basal medium supplemented with 
resveratrol, osteogenic differentiation medium, and osteogenic differentiation medium 
supplemented with resveratrol. Differentiation was analyzed over a period of 21 days. It 
is important to note that in all of the 2D study, hMSCs exhibited a normal proliferation 
curve with no significant difference in cell growth between the study groups. 
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Osteogenesis was assessed based on calcium, ALP, and OCN expression. 
Calcium expression was analyzed at days 7, 14, and 21 (Figure 5.2A). At each time point, 
cells cultured in osteogenic medium supplemented with resveratrol produced 
significantly higher amounts of calcium as compared to all other groups. Cells in basal 
medium with resveratrol as well as hMSCs cultured in osteogenic medium demonstrated 
a statistically higher level of calcium at days 14, and 21, as compared to the control. 
Calcium expression for hMSCs cultured in osteogenic medium with resveratrol is further 
demonstrated by Alizarin Red S Staining (Figure 5.2B) which shows a bright red color 
indicating mineralized matrix.  
Alkaline Phosphatase expression was determined at time points of 7, 14, and 21 
days. Cells cultured in osteogenic medium supplemented with resveratrol exhibited a 
statistically higher amount of ALP at every time point as compared to all other groups 
(Figure 5.2C). Cells cultured in basal medium with resveratrol as well as osteogenic 
medium showed significant ALP expression at day 21. ALP staining confirmed the 
expression at day 21 of culture in osteogenic medium with resveratrol, as shown by the 
bright purple-blue color of the cells (Figure 5.2D).  
Gene expression analysis of OCN demonstrated a significant higher level of gene 
expression in the basal medium supplemented with resveratrol at day 7 (Figure 5.2E). At 
days 14 and 21, cells cultured with resveratrol in osteogenic medium expressed 
statistically higher OCN, as compared to the control. Osteocalcin immunofluroescent 
staining further confirmed OCN level at day 21 expressed by hMSCs cultured in 12.5 μM 
resveratrol (Figure 5.2F). 
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Figure 5.1 Gene expression by M1 macrophages cultured under different resveratrol 
concentration was analyzed by measuring the levels of (A) IL-6, (B) TNF-α, (C) IL-10, 
(D) VEGF, and (E) MRC-1using qRT-PCR. A single asterisk denotes significantly 
higher as compared to groups denoted by two asterisks. Two single asterisk denotes 
significantly higher as compared to groups denoted by three asterisks. Results 
demonstrated the highest level M2 signatory genes in the presence of resveratrol 
demonstrating the potential to drive the pro-angiogenic and anti-inflammatory response. 
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Figure 5.2 (A) Calcium expression was the greatest for hMSCs cultured in osteogenic medium + 
resveratrol. (B) Alizarin Red S staining confirmed calcium deposition by hMSCs cultured in 
osteogenic medium + resveratrol at day 21, scale bar is100 μm. (C) ALP expression was the 
highest for hMSCs in osteogenic medium + resveratrol for each time point. (D) ALP staining of 
hMSCs at day 21 cultured in osteogenic medium + resveratrol, scale bar is 100 μm. (E) qRT-PCR 
showed the highest level of BGLAP in hMSCs in osteogenic medium + resveratrol for days 14 
and 21. (F) OCN staining of day 21 hMSCs cultured in osteogenic medium + resveratrol, scale bar 
is 50 μm. * denotes significantly higher as compared to groups denoted by **. ** denotes 
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5.9: Statistical Analysis 
Three samples (n=3) were analyzed per condition unless otherwise stated. Studies 
investigating the dose dependent effect of resveratrol on M1 macrophages and the effect 
of resveratrol on hMSCs were done in duplicate trials. Error bars in graphs represent 
mean ± standard deviation (SD). Two-way analysis of variance (two-way ANOVA) was 
calculated using GraphPad Prism software and used to determine statistical significance 
between experimental groups. One-way analysis of variance (one-way ANOVA) with a 
Tukey post-test was used to calculate significance between individual groups at different 
time points. Statistical significance was defined as p ≤ 0.05. 
5.10: Conclusions 
This study determined the effectiveness of resveratrol as a potent 
immunomodulator and promoter of osteogenesis. We set out to determine the dose 
dependent effect of resveratrol on M1 macrophage phenotype as well as the regulation of 
hMSC differentiation towards bone lineage.  
Our experiments investigating the dose dependent regulation of inflammatory 
cytokines by resveratrol indicated that M1 macrophages produce less IL-6 and TNF-α 
when cultured with the anti-inflammatory polyphenol. This is coupled with higher 
expression of anti-inflammatory markers VEGF, IL-10, and MRC-1 after 48 hours of 
exposure to resveratrol. Cells cultured with 25 μM resveratrol demonstrated the greatest 
expression of wound healing markers VEGF, MRC-1 and IL-10. Consistently, M1 
macrophages cultured with 25 μM resveratrol exhibited the lowest amount of 
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inflammatory cytokine TNF-α. Inflammatory marker IL-6 reduction by resveratrol was 
not statistically different between the 10 μM and 25 μM groups.  
To analyze osteogenic differentiation of hMSCs, we cultured cells in basal 
medium, basal medium with 12.5 μM resveratrol, osteogenic medium, and osteogenic 
medium with 12.5 μM resveratrol. Cells exposed to osteogenic medium supplemented 
with resveratrol produced significantly higher levels of calcium, alkaline phosphatase, 
and osteocalcin. These results altogether show the exciting potential for resveratrol to be 
used in tissue engineering approaches for attenuating host inflammation and stimulating 














 74   
 
 
CHAPTER 6: ENGINEERED RESVERATROL NANOPARTICLE-
INCORPORATED SCAFFOLDS TO DIRECT OSTEOGENIC DIFFERENTIATION 
OF HMSCS AND MODULATE INFLAMMATION OF M1 MACROPHAGES 
 
6.1: Introduction 
Biomaterial design is an essential component of successful bone tissue 
engineering strategies. The ideal scaffold should be osteoinductive, osteoconductive, and 
osteogenic. Osteoinductivity refers to the ability of a biomaterial to stimulate 
undifferentiated stem cells to develop into bone-forming cell lineage [312]. 
Osteoconductive scaffolds foster bone growth on the material surface by promoting cell 
attachment, proliferation, and allowing cell infiltration and matrix deposition [312, 313]. 
Osteogenicity signifies the scaffold contains cells that are able to differentiate into 
osteoblasts [314]. 
PLGA microsphere-sintered scaffolds are osteoconductive, and when combined 
with the appropriate cell source and signaling cues, become osteogenic as well as 
osteoinductive.  However, a significant challenge to bone tissue engineering strategies is 
biomaterial rejection due to the host immune response, as well as scaffold integration 
with the native tissue. In the previous chapter, we determined the ability of the natural 
compound resveratrol to synergistically modulate inflammation and stimulate 
osteogenesis of hMSCs in 2D.  
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The main objective of this study is to delineate the potential of resveratrol to 
accelerate the formation of bone and vasculature in tissue engineered scaffolds. The 
major hypothesis underlying our effort is that resveratrol can be used to simultaneously 
(1) induce the osteogenic differentiation of hMSCs seeded onto 3D porous scaffolds, and 
(2) switch the invading macrophages from a pro-inflammatory M1 to a pro-angiogenic 
M2 phenotype. We tested this hypothesis by assessing the time-dependent effect of a 
controlled release of resveratrol on macrophage gene expression as well as hMSCs 
osteogenic differentiation in 3D culture systems. Insufficient vascularization and lack of 
control on host inflammatory response to implantable scaffolds are profound barriers in 
regenerative medicine. The system developed in this study has the potential to be applied 
to bioengineering of other musculoskeletal tissues in addition to bone. 
 
6.2: Fabrication of PLGA Resveratrol Nanoparticles and Determination of Resveratrol 
Release Profile 
Nanoparticles with diameters of 150-350 nm were synthesized. Two different 
molecular weights of poly(lactic-co-glycolic acid) (PLGA) (Lactel Absorbable Polymers) 
were used to fabricate the resveratrol nanoparticles in order to test individual release 
profiles and optimize the resveratrol dosage in the 3D scaffolds (Table 6.1). A steric 
solution of 2.5% poly(vinyl alcohol) (Sigma) and 0.95 g of 2-morpholinoethanesulfonic 
acid monohydrate buffer (MES) (Sigma) pH of 5.0 in 100 mL of deionized water was 
created. The polymer-resveratrol conjugation solution was made by dissolving 100 mg of 
PLGA and 2.5 mg of resveratrol (Sigma) in 5 mL of acetone (Macron). The polymer-
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resveratrol solution was added drop-wise at a rate of 1 mL/minute to the steric solution 
while being stirred at 300 rpm. This colloidal suspension was stirred for 24 hours to 
ensure complete evaporation of acetone. Nanoparticles were harvested through a 
centrifugation step followed by lyophilization. 
Transmission Electron Microscopy (TEM) was used to analyze nanoparticle size. Briefly, 
nanoparticles were suspended in DI water and a drop of the solution was placed on a thin 
carbon film. The film was placed in a vacuum to allow for water evaporation and the 
sample was placed on a TEM grid. Images were taken using a JEOL 200CX transmission 
electron microscope. 
 Using a UV-Vis Spectrophotometer, a calibration curve was generated to 
correlate the absorption at 327 nm (peak absorbance of resveratrol) for various 
concentrations. Nanoparticles with different molecular weights were incubated in PBS at 
37°C, and the supernatant was collected every 24 hours to read the absorbance with the 
UV-Vis Spectrophotometer. As it will be shown in the results, the 75:25 PLGA 
demonstrated the optimum release profile and was selected for use in the remainder of 
experiments. 
6.3: Synthesis of PLGA Microsphere-sintered and Resveratrol Nanoparticle-incorporated 
Scaffolds 
Scaffolds with diameters of 10 mm and heights of 2 mm were fabricated 
according to established laboratory procedures [315-317]. Briefly, PLGA (85:15 lactide 
to glycolide ratio) (Lactel Absorbable Polymers) was dissolved in dichloromethane  
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Table 6.1. The chemical characteristics of PLGA used to design nanoparticles for 
resveratrol encapsulation and release in scaffolds. 
 
Lactide to Glycolide Ratio Molecular Weight (kDa) Functional Group 
75:25 75-100 Ester Terminated 




















 78   
(Sigma) to form a 1:4 w/v polymer solution. The solution was slowly poured into a 1% 
poly(vinyl alcohol) solution (Sigma) while being stirred at 330 rpm for 24 hours to allow 
for adequate evaporation of the solvent. Vacuum filtration was used to collect the 
microspheres, and the samples were washed with DI water and stored at -20°C for 24 
hours. The microspheres were lyophilized to completely remove all moisture. Micron 
sieves were used to isolate microspheres of diameter 500-700 μm. Microspheres of the 
size range 500-700 μm were placed into stainless steel molds, heated at 80ºC for 4 hours, 
and sintered into cylindrical disks. Scaffolds that were to be incorporated with 
nanoparticles were sintered for 3.5 hours to account for the additional sintering time 
needed to attach nanoparticles to the microspheres. 
 The target resveratrol release from the nanoparticles is based on 2D studies 
demonstrating the optimum resveratrol dose for hMSC differentiation [310, 318], and the 
desire to i) use acute inflammation to drive early osteogenesis and ii) switch macrophage 
phenotype to M2 after one week to promote wound healing and angiogenesis. To this 
end, initial resveratrol release is designed to attain 1-3 μM resveratrol for days 1-7, and 5-
12.5 μM for days 7-21 to optimize inflammation modulation and osteogenesis of hMSCs. 
To accomplish this, nanoparticles were suspended in DI water at a desired concentration 
of 180 μg resveratrol nanoparticles/μL based on the ratio of resveratrol to PLGA in the 
loaded nanoparticles (1:80). Next, 10 μL of the nanoparticle solution was placed on each 
scaffold and allowed to disperse throughout the substrate. Scaffolds with nanoparticles 
were sintered for an additional 30 minutes at 85ºC. 
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Nanoparticle incorporation onto the PLGA scaffolds was determined using 
Scanning Electron Microscopy (SEM). Briefly, scaffolds were dehydrated using an 
ethanol sequence (10, 30, 50, 70, 90, 95, 95, 100, 100%) for 15 minutes each. Scaffolds 
were dried overnight in a fume hood to allow for ethanol evaporation, and coated with 
gold/palladium. Scaffolds were observed under Zeiss Ultra Plus FESEM after coating. 
 
6.4: hMSC and Macrophage Seeding on Resveratrol-incorporated PLGA Scaffolds 
 
To confirm the effect of resveratrol on osteogenic differentiation, we analyzed the 
growth and lineage specification of hMSCs as cultured on resveratrol-incorporated 3D 
PLGA scaffolds. PLGA scaffolds were first sterilized by immersion in 70% ethanol for 
10 minutes. Scaffolds were washed 3x with PBS, and exposed to UV light for 1 hour per 
side to further sterilize the substrates. To seed cells on scaffolds, hMSCs were 
trypsinized, counted, centrifuged, and resuspended in basal medium at a concentration of 
2,500 cells/μL. Cell suspension was added to each scaffold at the amount of 20 
µL/scaffold. Samples were incubated for 20 minutes to ensure optimum cell attachment. 
Next, the remaining culture medium was placed in each well containing scaffolds. 
Culture medium was changed to osteogenic medium after 24 hour of incubation with 
basal media. Cell proliferation was assessed using MTS colorimetric assay. Osteogenic 
differentiation was analyzed based on the quantification of ALP and calcium expression. 
THP-1 monocytes were differentiated to M1 macrophages at a seeding density of 
50,000 cells/well of a 24 well plate. This was accomplished according to the protocol 
mentioned in the Chapter 5 Section 4. Resveratrol nanoparticle-incorporated scaffolds 
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were prepared using the method described in the Chapter 6 Section 3. Scaffolds were 
sterilized by immersion in 70% ethanol for 10 minutes followed by rinsing 3x with PBS. 
Scaffolds were placed under UV light for 1 hour per side. Scaffolds were placed in the 
wells with M1 macrophages and timepoints were taken at days 3, 7, 14, and 21. Gene 
expression of IL-6, TNF-α, IL-10, and VEGF was determined using qRT-PCR methods 
previously described in Chapter 5 Section 4. 
 
6.5: Statistical Analysis 
Three samples (n=3) were analyzed per condition unless otherwise stated. Studies 
investigating the osteogenic differentiation of hMSCs on resveratrol nanoparticle-
incorporated PLGA was done in duplicate trials. Error bars in graphs represent mean ± 
standard deviation (SD). Two-way analysis of variance (two-way ANOVA) was 
calculated using GraphPad Prism software and used to determine statistical significance 
between experimental groups. One-way analysis of variance (one-way ANOVA) with a 
Tukey post-test was used to calculate significance between individual groups at different 
time points. Statistical significance was defined as p ≤ 0.05. 
 
6.6: Results 
Resveratrol release from the nanoparticles and incorporation into PLGA scaffolds 
was assessed. Figure 6.1 includes the characterizations of PLGA scaffold with resveratrol 
encapsulated nanoparticle. We observed that scaffolds possessed an interconnected 
porous structure consisting of microspheres sintered together. We confirmed the 
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distribution of resveratrol nanoparticles throughout the scaffolds using SEM (Figure 
6.1A) and TEM (Figure 6.1B). The images demonstrated a homogenous spreading of 
nanoparticles (average diameter size of 250 nm) on the surface of microspheres. As 
expected, the nanoparticles were sintered into the PLGA scaffolds following the heating 
step, as manifested in high magnification images. To tune the release of resveratrol 
throughout the scaffolds, we varied the molecular weight of PLGA nanoparticles. Our 
goal was to design a sustained release of resveratrol over several days to give enough 
time for hMSC osteogenic differentiation and stimulate M1 to M2 differentiation. Figure 
6.1D demonstrates the release profile of resveratrol from nanoparticles embedded in 
scaffolds. As expected, the higher molecular weight of 75-100 kDa allowed for a 
prolonged controlled release of resveratrol within 3D PLGA sintered microsphere 
scaffolds. 
Resveratrol nanoparticle-incorporated scaffolds control macrophage polarization 
and enhance osteogenic differentiation of hMSCs. M1 macrophages were cultured on 
resveratrol incorporated PLGA scaffolds for 21 days, and inflammatory gene expression 
was analyzed at different time points (Figure 6.2). We observed the expression of IL-6 
expression to sustain in day 3 to day 7 time points, and significantly drop by day 14 
(Figure 6.2A). Consistently, the gene expression of inflammatory marker TNF-α was 
significantly lower on later time points (Figure 6.2B). On the other hand, IL-10 and 
VEGF expression were upregulated at day 7 and 14 time points (Figure 6.2C-D). These 
results were consistent with our 2D experiments in that resveratrol downregulates the 
inflammatory markers while stimulating the expression of angiogenic genes. A difference  
 





Figure 6.1 (A) SEM image of a resveratrol nanoparticle-incorporated scaffold showing the 
nanoparticles on the surface of the sintered microsphere scaffolds PLGA. (B) SEM image 
of a blank PLGA scaffold (control) demonstrating a smooth surface without nanoparticles. 
(C) TEM image of individual resveratrol encapsulated nanoparticles. The approximate 
diameter of nanoparticles was 250 nm. (D) Resveratrol release profile from the scaffolds 
demonstrated a slower and more linear release when conjugated with a higher molecular 
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however is manifested in the amounts of these genes due to the 3D nature of scaffolds 
and the release profile of resveratrol on scaffolds versus 2D condition.  
Figure 6.3 demonstrates the results of hMSCs cultured on tissue culture 
polystyrene (TCPS), 3D PLGA scaffolds, and 3D resveratrol nanoparticle-incorporated 
PLGA scaffolds. We observed that the cells grow in all conditions; however, hMSCs 
cultured on TCPS medium had significantly higher cell numbers than both the PLGA and 
PLGA with resveratrol groups (Figure 6.3A). Furthermore, the cells cultured on blank 
PLGA reached a significantly higher number compared to hMSCs grown on PLGA with 
resveratrol nanoparticles.  
hMSCs cultured on resveratrol incorporated scaffolds demonstrated significantly 
greater of ALP expression compared to all other experimental groups at days 3, 7, 14, and 
21, while hMSCs on PLGA scaffolds produced the second highest amount of ALP at 
each time point as compared to TCPS (Figure 6.3B). Consistently, hMSCs cultured on 
resveratrol nanoparticle scaffolds expressed a significantly higher amount of calcium at 
days 14 and 21. hMSCs on blank PLGA scaffolds produce the second highest amount of 
calcium a compared to the control TCPS (Figure 6.3C). These results were consistent 
with the 2D experiments demonstrating the potential of resveratrol to promote osteogenic 
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Figure 6.2 Gene expression analysis of M1 macrophages on the resveratrol 
incorporated scaffolds demonstrated (A) IL-6 expression at days 3 to 7, 14 and 21 
post-culture. (B) TNF-α expression at days 3 to 7, 14 and 21 post-culture. A single 
asterisk denotes a significantly higher expression of TNF-α at day 3 compared to 
the previous time point. (C) IL-10 expression at days 3 to 7, 14 and 21 post-
culture. (D) VEGF expression at days 3 to 7, 14 and 21 post-culture. A single 
asterisk denotes a significantly higher expression of VEGF at day 21. * denotes 
significantly higher as compared to groups denoted by **. ** denotes significantly 
higher as compared to groups denoted by ***. Results demonstrated the highest 
level M2 signatory genes in the presence of resveratrol demonstrating the potential 
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Figure 6.3 (A) hMSC proliferation on scaffolds showed a normal cell growth 
curve. (B) ALP expression by hMSCs on TCPS, PLGA scaffolds and PLGA 
scaffolds with resveratrol nanoparticles. (C) ALP expression by hMSCs on 
TCPS, PLGA scaffolds and PLGA scaffolds with resveratrol nanoparticles. * 
denotes significantly higher as compared to groups denoted by **. ** denotes 
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6.7: Discussion  
Our study addresses fundamental issues facing osseointegration of biomaterial 
grafts in an inflammatory microenvironment. We set out to engineer an 
immunomodulatory and osteoinductive scaffold that can harness the osteogenic and 
wound healing potential of immune cells, as well as program hMSCs towards bone tissue 
formation. To accomplish this goal, we demonstrated the ability of resveratrol to control 
macrophage phenotype from inflammatory to wound healing as well as stimulate 
osteogenic differentiation of hMSCs. Building on these 2D and 3D proof-of-concept 
experiments, we designed a specific resveratrol nanoparticle release profile within PLGA 
scaffolds that would i) control macrophage phenotype and subsequent cytokine secretion 
and ii) drive the osteogenic differentiation of hMSCs. This resveratrol nanoparticle 
incorporated scaffold is a novel approach to enhance graft integration and assimilation 
with native tissue. 
Researchers have explored many options to modulate the immune response to 
prevent biomaterial rejection, such as using polymeric coatings, steroidal anti-
inflammatory drugs, and angiogenic factors. These methods have faced many limitations 
due to immunogenicity, decomposition during the manufacturing process, and poor 
adhesion characteristics. Anti-inflammation pharmaceutical drugs only temporary 
suppress inflammation and have been known to reduce angiogenic factors which in turn 
delays wound healing. Finally, despite their important role in inflammatory cascade of 
events, the use of angiogenic growth factors is only partially effective due to its 
physiologic side effects.  
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Instead of trying to counteract inflammation, our approach aims to utilize a 
natural polyphenol to regulate immune cell behavior and use their expressed signaling 
molecules to drive the osteogenic differentiation of hMSCs. Our methods build on the 
central concepts of the anti-inflammatory and osteogenic properties of resveratrol as well 
as the known angiogenic signaling molecules produced by macrophages. To this end, we 
fabricated resveratrol nanoparticle-incorporated scaffolds with a controlled release profile 
that have the potential to revolutionize biomaterial assimilation with native bone tissue. 
Our 2D proof of concept experiments described in Chapter 5 signify that  M1 
macrophages secrete less IL-6 and TNF-α when exposed to resveratrol.  Furthermore, we 
found that M1 macrophages produce higher levels of anti-inflammatory markers VEGF, 
IL-10, and MRC-1 after 48 hours of culture with the anti-inflammatory polyphenol. From 
our results, we determined that 25 μM resveratrol tempers inflammation to the greatest 
extent as compared to the other concentrations. However, the optimized time scale and 
amount of resveratrol released from the nanoparticles should account for the target 
temporal concentration for both osteogenesis and macrophage phenotype polarization.  
The use of resveratrol as a stimulator of osteogenesis has been previously 
demonstrated for hMSCs, human adipose derived stem cells (hADSCs), and pre-
osteoblastic MC3T3-E1 cells [308-311, 318-323]. Furthermore, studies have shown 
resveratrol to affect proliferation and osteogenesis in a dose-dependent manner. hADSCs 
cultured with 12.5 μM, 25 μM, and 50 μM resveratrol showed the highest proliferation 
rate when exposed to 12.5 μM resveratrol, and the highest levels of ALP when cultured 
with 25 μM resveratrol. Doses of 50 μM resulted in extremely low cell numbers and ALP 
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production. ADSCs cultured with resveratrol exhibited the highest levels of osteocalcin 
and osteoprotegerin at a concentration of 12.5 μM [318]. Another study concluded that 
doses of 25 μM resveratrol are potentially cytotoxic, and that 12.5 μM resveratrol results 
in the greatest mineralized matrix after 4 weeks in vivo [310]. Additionally, hMSCs 
cultured with varying doses of resveratrol produced the highest calcium deposition and 
greatest proliferative capabilities when exposed to a concentration of 10 μM [323]. Based 
on these studies, and the fact that M1 macrophages switch phenotype to M2 when 
exposed to doses as low as 1 μM resveratrol, we selected a target resveratrol 
concentration of 12.5 μM to stimulate osteogenesis of hMSCs in 2D. Consistent with 
these, we observed the greatest calcium deposition and ALP expression from cells 
cultured in osteogenic medium + 12.5 μM. Furthermore, OCN levels were the highest for 
hMSCs cultured in osteogenic medium + 12.5 μM. To optimize macrophage control and 
osteogenic differentiation of hMSCs, we targeted a nanoparticle release profile of 
approximately 1-3 μM resveratrol per day for days 1-7, then approximately 5-12.5 μM 
resveratrol per day for days 7-21. 
To design a biomaterial that allows for modulation of immune response, one must 
first determine how specific aspects of inflammation, such as macrophage phenotype, 
influence wound healing and osteogenesis. Preliminary investigations on total joint 
replacement materials and the surrounding tissue histology from either i) joints that had 
become loose due to osteolysis, and ii) joints implanted in osteoarthritic patients, have 
found that the former tissue produced many pro-inflammatory M1 macrophages while the 
latter demonstrated wound healing M2 macrophages [324, 325]. In another recent study, 
 
 89   
porosity was found to drive a higher ratio of M2/M1 macrophages when compared to the 
non-porous control [326]. Furthermore, scaffolds composed of natural ECM can switch 
macrophage phenotype to predominantly wound healing by 7-14 days after implantation 
[327-329]. The common thread that relates all these findings is that they all rely on 
altering the cytokine release profile by monocyte and macrophages to attenuate the 
inflammatory response to the biomaterial [330, 331].  
Although chronic inflammation is detrimental to wound healing and assimilation 
of graft with native tissue, recent studies have demonstrated the benefits of monocytes 
and macrophages in stimulating osteogenic differentiation of stem cells. In a recent 
published work, hMSCs were cultured in conditioned medium (CM) from M1 
macrophages, M2 macrophages, and monocytes, and analyzed for hallmark osteogenic 
markers such as RUNX2, ALP, and bone morphogenetic protein-2 (BMP-2). hMSCs 
cultured with M1 CM expressed the highest levels of RUNX2, ALP, and BMP-2 [332]. 
Another study demonstrated that a member of the IL-6 pro-inflammatory cytokine 
family, Oncostatin M (OSM), produced by M1 macrophages promoted osteogenic 
differentiation of hMSCs and inhibited adipogenesis [333]. Macrophages secrete several 
osteogenic signaling molecules such as bone morphogenic protein-2 (BMP-2), 1, 25-
dihydroxyvitamin D3, interleukin-1 beta (IL-1β), and IL-6 [334-336]. During fracture 
healing, cytokine members of the TGF- β superfamily, such as BMP, promote different 
stages of wound repair. BMP-2 peaks in expression levels early in the healing process, 
mediates a cascade of other BMPs associated with intramembranous and endochondral 
ossification [337]. TNF-α is another cytokine secreted by macrophages during the initial 
 
 90   
inflammatory response that is responsible for recruiting hMSCs, and promoting cell 
survival [338]. Additionally, macrophages secrete angiogenic growth factors such as 
VEGF and PDGF, and these cytokines are important mediators in bone remodeling. 
Specifically, the VEGF family recruits endothelial cells, osteoblasts, and osteoclasts, and 
can promote microvascular endothelial cells to secrete BMPs in a hypoxic 
microenvironment found in fractured bone tissue [339-341].  
In our proof of concept 3D experiments, we were able to successfully engineer a 
scaffold with a specific resveratrol release profile. M1 macrophages and hMSCs were 
individually placed on the scaffolds and cultured for 21 days. The gene expression profile 
of the macrophages showed moderately high expression of IL-6 for day 3 and day 7, and 
was significantly reduced by day 14. VEGF expression levels were relatively low until 
day 14, but significantly increased by day 21. This in itself overcomes a critical factor in 
tissue engineering approaches since lack of vascularization generally leads to failure of 
the graft. Our method of inducing endogenous VEGF secretion from native macrophages 
keeps levels physiologically relevant, therefore the risk of overexposing surrounding 
tissue to high levels of this angiogenic growth factor is almost nonexistent. 
Stem cells cultured on the resveratrol-incorporated scaffolds expressed the highest 
levels of calcium and ALP, demonstrating the effectiveness of the controlled resveratrol 
release. The mechanism by which resveratrol induces osteogenesis is under deep 
investigation. Preliminary work by scientists has shown resveratrol to trigger Wnt 
signaling pathway leading to the upregulation of RUNX2 expression, the transcription 
factor essential for cell differentiation into osteoblasts [308, 342]. Resveratrol also 
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promotes osteogenesis through SIRT-1, and it has been shown that FOXO3A protein 
expression and SIRT-1 activation operate synergistically to mediate RUNX2 gene 
transcription [309, 322]. When embryonic stem cell-derived mesenchymal progenitors 
are cultured in adipogenic medium containing resveratrol, RUNX2 and OCN are 
upregulated while adipogenic genes PPARγ2 and LEPTIN are suppressed [322]. This is 
extremely important because PPARγ2 can prevent RUNX2 transcription and inhibit 
osteogenesis [343, 344]. Further studies are warranted to illucidate the temporal effect of 




For the first time, we demonstrated a novel approach based on the use of 
resveratrol to concurrently modulate inflammation, stimulate angiogenic growth factor 
release, and promote osteogenesis. Our results demonstrated the polarization of M1 
macrophages from pro-inflammatory to wound healing M2 macrophages releasing pro-
angiogenic growth factor VEGF.  Resveratrol also accelerated the osteogenic 
differentiation of hMSCs in both 2D and 3D tissue engineering culture systems. 
Strikingly, the temporal release profile and amount of resveratrol can be tuned at the 
same time to concurrently promote osteogenesis and M2 polarization. Together, this 
study introduces a ground breaking synergistic method to overcome prolonged 
inflammation in response to implanted biomaterials in bone tissue engineering strategies, 
 
 92   




























CHAPTER 7: SUMMARY OF FINDINGS 
 
The results of the research presented in this dissertation show methods of 
directing stem cell differentiation towards bone tissue using 3D engineered substrates. 
Additionally, these findings demonstrate a novel approach for harnessing inflammation to 
accelerate wound healing and promote osseointegration of implanted scaffolds with 
native host tissue. This was accomplished by three main studies.  
The first investigated the use of decellularized scaffolds containing native bone 
extracellular matrix to direct hESC differentiation towards osteogenic lineage. 
Osteomimetic PLGA scaffolds were fabricated by utilizing a microsphere-sintering 
technique, followed by seeding hOBs on the substrates for 14 days in order to deposit 
bone ECM on the surface of the polymer. Analysis of the scaffold following hOB 
decellularization indicated that the deposited ECM had a similar composition to that of 
bone ECM found in vivo. The potential of these scaffolds as bone graft substitutes was 
evaluated by the in vitro differentiation of hESCs on the osteomimetic substrates. The 
decellularized scaffolds promoted cell adhesion, proliferation, and osteogenic 
differentiation. Incorporating native components of bone ECM with PLGA scaffolds has 
proven to be a successful approach to tissue engineering bone, however a more 
meticulous study is warranted to parse the in vivo mechanisms by which ECM proteins 
regulate osteogenesis.  
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The next study determined the effectiveness of resveratrol as a modulator of 
inflammation and promoter of osteogenesis in 2D. Our experiments investigating the 
dose dependent regulation of inflammatory cytokines by resveratrol demonstrated that 
M1 macrophages produce less IL-6 and TNF-α when cultured with resveratrol. This is 
paired with greater expression levels of anti-inflammatory markers VEGF, IL-10, and 
MRC-1 after 48 hours of exposure to the anti-inflammatory polyphenol. M1 macrophages 
cultured with 25 μM resveratrol demonstrated the greatest expression of wound healing 
markers VEGF, MRC-1 and IL-10. Consistently, M1 macrophages cultured with 25 μM 
resveratrol exhibited the lowest amount of inflammatory cytokine TNF-α. Inflammatory 
marker IL-6 reduction by resveratrol was not statistically different between the 10 μM 
and 25 μM groups. After investigating the immunomodulatory effects of resveratrol, we 
examined how resveratrol influences hMSC lineage commitment. To analyze osteogenic 
differentiation of hMSCs, we cultured cells in basal medium, basal medium with 12.5 μM 
resveratrol, osteogenic medium, and osteogenic medium with 12.5 μM resveratrol. Cells 
exposed to osteogenic medium supplemented with resveratrol expressed significantly 
higher levels of calcium, alkaline phosphatase, and osteocalcin as compared to the 
controls. These results altogether show the exciting potential for resveratrol to be used in 
tissue engineering approaches for attenuating host inflammation and stimulating 
osteogenic differentiation, and can be applied to a 3D scaffold design to integrate 
resveratrol. 
The last study investigated the incorporation of resveratrol in 3D scaffolds, and 
observed the efficacy of these scaffolds for immunomodulation and osteogenesis. For the 
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first time, we demonstrated a novel approach based on the use of resveratrol to 
concurrently modulate inflammation, stimulate angiogenic growth factor release, and 
promote osteogenesis. Our results indicated the phenotypic switch of M1 macrophages 
from pro-inflammatory to wound healing M2 macrophages on the resveratrol-
incorporated scaffolds. Along with secreting anti-inflammatory cytokines, the M2 
macrophages released pro-angiogenic growth factor VEGF.  Furthermore, resveratrol 
integrated scaffolds accelerated the osteogenic differentiation of hMSCs as compared to 
cells on control PLGA and TCPS. The temporal release profile and amount of resveratrol 
leaving the nanoparticles can be tuned to concurrently promote osteogenesis and 
macrophage polarization. This study introduces a ground breaking synergistic method to 
overcome inflammation in response to implanted biomaterials in bone tissue engineering 
strategies, and to harness the inflammatory response towards successful osseointegration 
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CHAPTER 8: FUTURE WORK 
 
• Parse the in vivo mechanisms by which ECM proteins regulate osteogenesis  
• Determine which ECM components have the greatest effect on osteogenic 
differentiation of hESCs cultured on osteomimetic PLGA  
• Implant osteomimetic scaffold in animal model to study in vivo capabilities of the 
graft to repair a critical size defect in bone  
• Investigate the interplay between hMSCs and macrophages (M0, M1 and M2) in 2D  
• Determine how macrophages regulate the osteogenic differentiation of hMSCs on 3D 
resveratrol-incorporated scaffolds 
• Implant resveratrol PLGA scaffolds in animal model to investigate how the scaffold 
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